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ABSTRACT 
 
The objective of these studies was to investigate the satiety effects of foods typically 
consumed as part of a breakfast meal, and a novel fat emulsion designed to stimulate satiety 
signals. The first study compared the satiety effects of oatmeal with a popular ready-to-eat 
breakfast cereal (RTEC). The second study assessed the effects of the fat emulsion Olibra™, on 
satiety, food intake, and body weight. 
Forty-eight healthy individuals, ≥18 years of age were enrolled in a randomized 
controlled crossover trial. Following an overnight fast, subjects consumed either oatmeal or 
RTEC in random order at least a week apart. Visual analogue scales (VAS) of appetite and 
satiety were completed at baseline, and 30, 60, 120, 180 and 240 minutes postprandial. Appetite 
and satiety scores were analyzed by area under the curve (AUC) assessed across the time-points. 
Oatmeal, resulted in greater increase in fullness (AUC: p=0.005 [120min: p=0.0408, 180min: 
p=0.0061, 240min: p=0.0102]) than the RTEC. Hunger (AUC: p=0.0009 [120min: p=0.0197, 
180min: p=0.0003, 240min: p=0.0036]), desire to eat (AUC: p=0.0002 [120min: p=0.0168, 
180min: p<0.0001, 240min: p=0.0022]), and prospective intake (AUC: p=0.0012 [120min: 
p=0.0058, 180min: p=0.006, 240min: p=0.0047]) decreased to a greater extent with oatmeal as 
compared with the RTEC.  
In the study investigating Olibra™, 82 subjects (18-60 years of age, body mass index: 25-
40 kg/m2) were enrolled in a randomized, placebo-controlled, double-blind, parallel trial. During 
a 12-week period, the effects of Olibra™ fat emulsion (2.1g twice daily) on food intake, appetite, 
satiety, weight, and body composition were compared with those of a twice daily administered 
placebo (1.95g milk fat). Data relating to 71 subjects were analyzed using analysis of covariance. 
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Differential weight and waist circumference reductions were not significant. Differential group 
effects were not significant for body fat, waist-hip ratio, food intake, appetite, and satiety.  
The studies showed that oatmeal increased satiety to a greater extent than the RTEC in 
the four hour period post-prandial; however, consumption of Olibra™ had no effect on satiety or 
food intake. Additionally, daily consumption of Olibra™ had no effect on body weight or body 
composition at the end of 12 weeks.  
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CHAPTER 1 
INTRODUCTION 
 
The results from the latest National Health and Nutrition Examination Survey 
(NHANES) showed that in 2009-2010, the prevalence of obesity in the United States was 35.5% 
among adult males, 35.8% among adult females,1 and 16.9% among children and adolescents.2 
Despite evidence of a leveling off in the steep rises previously observed1, 2 the number of obese 
individuals in the world today is higher than it has ever been.3  Weight gain is the result of a 
chronic energy imbalance. The decision to eat rarely arises out of a biological deficit. More 
likely, it is appetite sensations interacting with environmental and social cues that trigger meal 
initiation.4 In this context, appetite and satiety become important elements in the adjustment of 
energy intake to expenditure.  
Appetite and Satiety 
Appetite is controlled by a complex sequence of interactions among elements that form a 
psychobiological system. This system is bound by interrelationships between the external 
environment, psychological and behavioral profiles, physiological responses, and neural 
mechanisms.5 The intra-meal processes generated by ingestion which result in termination of a 
meal are collectively referred to as satiation and the suppression of the desire to eat, decline in 
hunger, and increase in fullness after a meal is eaten is referred to as satiety.6 Although satiation 
and satiety are distinct concepts, they act together along with myriad other factors to determine 
eating behavior.7 Appetite and satiety are states of the moment, liable to change with the 
availability of food and drink, the combination of foods consumed, and changes in the physical 
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and social contexts.8 Nevertheless, appetite and satiety have been shown to be good predictors of 
food intake.9, 10 
Eating behavior is influenced by metabolic and sensory factors. The metabolic factors 
include the neural and hormonal signals arising from the gastrointestinal (GI) tract and conveyed 
to the brain, whereas the sensory factors include learned responses, and the reward value 
attached to a food. The satiating power of a food depends on its ability to mediate the right 
balance (one that results in satiation or satiety) between sensory, cognitive, post-ingestive (but 
pre-absorptive), and post-absorptive events and processes that comprise what is called the 
‘satiety cascade’ proposed over 20 years ago.7 The satiety cascade has subsequently been 
modified to include liking (orosensory stimulation of food) and desire (motivation to engage in 
eating).11 Sensations of hunger, fullness, desire to eat, and prospective consumption, are indices 
of the drive for food and reflect the strength of satiety.  
Functional foods  are defined as components of the usual diet that may provide health 
benefits beyond basic nutrients.12 A functional food may influence satiety by providing fewer 
kilocalories (kcals) while maintaining the same weight or volume of the original food, resulting 
in the consumption of less energy. However, the difficulty arises in ensuring that compensatory 
homeostatic mechanisms do not come into play to defeat the purpose of the reduction in energy 
intake. Alternatively, the food could be engineered to contain elements that strengthen the satiety 
signals thereby prolonging the interval between meals when hunger or the desire to eat return.13  
Macronutrients can influence the satiating power of a food.14 Thus, manipulating the 
specific macronutrient compositions of foods as a means of enhancing satiety and regulating 
food intake is a valid proposition. Evidence suggests that diets with relatively high protein 
content contribute to weight loss and weight maintenance. These effects on energy balance are 
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largely mediated by enhanced energy expenditure and protein-induced satiety.15 The satiating 
effect of carbohydrates is determined by the type as well as the form of carbohydrate. Fiber 
influences satiety largely through its bulking and viscosity properties.16 The role of high and low 
glycemic index (Gi) carbohydrate foods in satiety is not resolved fully.17, 18 Data from human 
intervention studies do not appear to support a role for short chain fatty acids derived from 
colonic fermentation of undigested carbohydrates and protein in appetite regulation.19-21 Fat 
generates satiety signals,22 but it increases the energy density of a food. This seeming 
contradiction notwithstanding, the physicochemical properties of fat have been manipulated to 
induce satiety.23-25 
Protein 
Satiety mediated by protein is closely related to increases in energy expenditure. Protein 
intake influences energy expenditure primarily through its effects on diet induced thermogenesis. 
The thermic effect of nutrients is related to the adenosine triphosphate required for metabolism, 
storage, and oxidation.15 Three phosphate bonds are used for the incorporation of each amino 
acid into protein.26 The body is unable to store protein under conditions of high protein intake, 
and has to metabolize it, which increases thermogenesis. Additionally, elevated concentrations of 
blood and plasma amino acids, which cannot be channeled into protein synthesis, activate satiety 
mechanisms.15 Further, it has been hypothesized that protein induced satiety is related to 
increased concentrations of the anorexigenic hormones glucagon-like peptide-1 (GLP-1) and 
peptide YY (PYY) and a decrease in the orexigenic hormone ghrelin.27, 28 
Dietary Fiber 
The means by which dietary fiber influences satiety is related to its intrinsic physical and 
chemical properties.16 Soluble fibers, by their inherent ability to absorb water, form gels that 
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contribute to gastric distension. Viscous fibers which include many soluble fibers such as gums, 
pectins, sea weeds, alginates and ß-glucans induce thickening when mixed with liquids.29 
Consumption of highly viscous soluble dietary fiber delays gastric emptying which can increase 
stomach distension30 thereby stimulating afferent vagal signals of fullness.4 Increased viscosity 
of intestinal contents reduces the absorption rate of nutrients. Exposure of the intestinal mucosa 
to nutrients stimulates the release of peptides that affect satiety.31 The degree of viscosity  
however depends on the chemical composition and concentration of the specific fiber.32 
Additionally, energy density is inversely associated with  satiety.33  Dietary fiber, by  lowering 
the energy density of a food34 enhances satiety. 
Fat 
Fats have been shown to reduce hunger when present in the GI tract by eliciting satiety 
signals.22 Fat in the  duodenum stimulates the release of cholecystokinin and other 
gastrointestinal peptides that affect satiety.31 Exposure of the ileum to fat stimulates an even 
larger satiety response than exposure to the duodenum.35 Fat reaching the ileum stimulates an 
inhibitory feedback mechanism referred to as the ileal brake. Activation of the ileal brake is 
mediated through an interaction of neural and hormonal signals31 which delays gastric 
emptying36, 37 prolongs GI transit time,37 and influences satiety.38, 39 The ability of fat to regulate 
GI motor function, depends on its physicochemical properties. While long chain fatty acids 
(LCT) (>12 carbons) are more potent effectors of GI satiety signals than shorter chain fatty acids 
(≤10 carbons),40, 41 medium chain triglycerides  (MCT) (6-12 carbons) have been shown to 
influence satiety through increased energy expenditure.42 Unlike LCT, MCT are directly 
absorbed into portal circulation and are more rapidly metabolized. Reports on the effects of the 
degree of saturation on satiety are conflicting.43, 44 
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Olibra™ is a fat emulsion that has been demonstrated in some studies to increase satiety 
and reduce food intake23-25  however, the effects have not been replicated in other studies.45-48 
Oats contain significant amounts of the soluble fiber ß-glucan, which exhibits high flow 
viscosities at relatively low concentrations.49 Among breakfast products, oatmeal was found to 
induce the highest level of satiety in a study to assess the satiating capacities of several foods.50 
Thus, as satiety-enhancing functional foods, Olibra™ and oatmeal appear to be targets that merit 
investigation. 
Justification 
The biological drive to eat is inextricably linked to the satiating power of a food, and 
thereby to the adjustment of energy intake to energy expenditure. Although weight loss is 
complex and difficult, enhancing satiety is a legitimate means of facilitating the process 
especially if the proposed food forms part of a culturally accepted eating pattern such as regular 
consumption of a breakfast meal. The concept of the satiety cascade implies that different 
nutritional components of a food will interact in different ways with the mediating processes to 
result in varying effects on satiety.5 Thus, in helping people to eat less, exploring the field of 
satiety through the use of functional foods is worthy of consideration. 
Research Questions 
1. Does consumption of Olibra™ result in an increase in satiety and a reduction in food intake 
that causes weight loss?   
2. Does consumption of oatmeal enhance satiety as compared with an isoenergetic serving of an 
oat-based ready-to-eat breakfast cereal (RTEC)? 
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Hypotheses 
1. Consumption of Olibra™ will result in an increase in satiety and a reduction in food intake 4 
hours and 9 hours postprandial. 
2. Daily consumption of Olibra™ will result in an increase in satiety and a reduction in food 
intake at the end of four weeks. 
3. Daily consumption of Olibra™ will result in weight loss at the end of 12 weeks. 
4. Consumption of oatmeal will result in greater satiety than the RTEC, over the 4 hour period 
following consumption.  
Objectives 
1. To evaluate the effect of Olibra™ on subjective satiety and food intake, acutely and after 
four weeks. 
2. To evaluate the effect of Olibra™ on body weight and body composition after 12 weeks. 
3. To compare the subjective satiety ratings of oatmeal with a popular oat-based RTEC over the 
four hour period following consumption. 
Limitations 
1. Hormone levels were not measured; hence, it is difficult to draw any definitive conclusions 
on the effects of hormones on appetite and satiety. 
2. Although subjects were asked to maintain a 10-12 hour overnight fast, there was no control 
exercised over subjects’ food intake prior to each test day which may have influenced the 
results. 
3. Relatively small convenience samples including predominantly female subjects were used; 
thus, the generalizability of the results is compromised. 
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4. The effects of oatmeal or the RTEC preload on subsequent food intake were not measured; 
thus, the effects on regulation of food intake are unknown. However, as part of a multi-stage 
proof of concept, effects of oatmeal on food intake and body weight can be assessed in future 
studies.  
5. The study comparing the effects of oatmeal and the RTEC only measured short term satiety; 
thus, the possibility of recurrent activation of the satiating mechanisms was not assessed. 
6. The nutrient contents of the two cereals were not matched; thus, the effects of each nutrient 
on satiety could not be clearly differentiated. 
7. No information on subjects’ usual intake was obtained, to determine if previous patterns of 
nutrient exposure were related to the results of the study investigating the effects of Olibra™ 
on satiety. 
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CHAPTER 2 
REVIEW OF LITERATURE 
 
Introduction 
Overweight and obese individuals are at an increased risk for several medical conditions 
that contribute to morbidity and mortality.51 According to the latest results of NHANES, in 2009-
2010, 69.2% of adults in the United States (US) and 16.9% of children and adolescents were 
overweight or obese.1, 2 The prevalence of obesity among both males (35.5%) and females 
(35.8%) has not significantly changed in the two most recent years, as compared with the 
previous six years.1 Despite the evidence for a leveling off in the prevalence of obesity,3 it is 
predicted that by 2030, 86.3% of all adults in the US will be overweight or obese.52 The 
accompanying rise in health care costs is expected to account for 16-18% of total US health care 
costs (860.7 to 956.9 billion US dollars) by 2030.52 Despite a high per capita expenditure on 
health care, life expectancy in the US ranked 34th in the world in 2009.53 The unusually high rate 
of obesity in younger age groups, and higher rates of severe obesity in the US, have contributed 
to the reduction in life expectancy as compared with other countries.54  
Obesity, is a multifaceted problem with complex contributing factors, including genetics, 
hormone levels,55 behavioral patterns, and their environmental determinants.56 Obesity results 
from a small but chronic energy imbalance. The impetus to initiate a meal is rarely based on a 
biological deficit. More likely, it is appetite sensations that trigger an eating episode.57 The 
disease burden from excess weight58 calls for novel strategies aimed at achieving healthier 
weights. Weight loss is complex and difficult, and controlling appetite may not be the solution, 
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but it is certainly a means of facilitating the process, especially if the proposed food is consumed 
regularly as part of a culturally accepted eating pattern such as breakfast. 
Appetite and Satiety 
Appetite is controlled by a network of interactions referred to as the psychobiological 
system, and reflects the synchronous operation of events occurring on three levels: 1) 
psychological events and behavior, 2) peripheral physiology, and 3) the central nervous system.5 
However, apart from the desire to satisfy their appetite sensations, humans are also prompted to 
eat by sensory hedonics, sensory stimulation, tension reduction, social pressure, and boredom.4 
Thus, a broad definition of appetite would encompass the whole field of food intake, selection, 
motivation, and preference.7  
Satiety is the process that inhibits further eating, causes a decline in hunger, and an 
increase in fullness after a meal is eaten, whereas, the inhibitory processes that lead to 
termination of a meal cause satiation. Although satiation and satiety are distinct concepts, they 
act together along with other factors to determine eating behavior.7 The satiety cascade provides 
a framework for examining the processes (sensory, cognitive, post-ingestive, and post-
absorptive) that mediate the satiating effect of foods.5 A modification to the satiety cascade 
includes the concepts of ‘liking’ which is the pleasure derived from the oro-sensory stimulation 
of food and ‘wanting’ which refers to the desire or motivation to actually engage in eating.11  
Eating behavior is controlled by metabolic factors that drive appetite and satiety, and 
sensory factors that drive food choice.  In the brain, the sensory signals of food are linked to the 
metabolic consequences leading to a conditioning of eating and nutrition patterns. Cognitive 
factors such as an estimation of the satiating effect of foods, and the timing of the next meal 
intervene and contribute to making eating a learned behavior.7 It has been argued that food intake 
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is controlled by an integrated set of signals at a momentary level, liable to change with the 
environment in which food is available, as each combination of items is consumed, and with 
every change in the physical and social context.8 By this argument, food intake tests and appetite 
rating scales fail in their assessment of satiety as they do not account for the changing influences 
over eating within, before, or after the test period, reactive responses, and the rater’s mental state 
at the moment that the quantitative judgment is being expressed.59  
Short term control of eating is influenced by episodic signals that arise largely from the 
GI and are generated periodically as food intake occurs. The peptides involved in GI signaling 
include cholecystokinin, GLP-1, PYY, and ghrelin. Long term control of eating, also referred to 
as tonic signaling, reflects the metabolic state of adipose tissue. Tonic or enduring effects 
influence traits (stable predispositions) whereas episodic or transient control influences states 
(dispositions subject to rapid fluctuations).60 Psychometric tests such as the Eating Inventory61 
are used to identify traits that predispose individuals to opportunistic eating. States reflect the 
drive to eat, are expressed as appetite ratings, and are measured using VAS.60  
In a review of 80 studies4 that assessed satiety using subjective ratings of appetite, or by 
measuring actual energy intake, the vast majority of the studies showed that appetite ratings 
correlated with food intake in a standardized setting. Further, subjective appetite ratings and food 
intake were associated with changes in hormone concentrations.4 Subjective satiety responses 
usually coincide with the time of occurrence and magnitude of the effect of physiological 
processes such as stomach filling, and the absorption of nutrients.7 Nevertheless, satiety claims 
do not need to be substantiated by physiologic data.13 It has been demonstrated that appetite 
scores measured through VAS can be reproduced and are therefore feasible tools to measure 
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appetite and satiety sensations.7, 62, 63  Moreover, appetite and satiety have been found to be good 
predictors of food intake.9, 10  
Functional foods  are defined as components of the usual diet that may provide health 
benefits beyond basic nutrients.12 Ingredients contained in functional foods can help consumers 
gain control over their eating behavior.13 Foods that influence satiety may counteract 
impairments in satiety hormone production or response to ingestion, thereby modulating the 
behavioral response to ingestion.6 While some functional foods may produce short term effects 
on appetite regulation others may have more enduring effects that translate into reductions in 
body weight; however, both have value in helping consumers to resist the situational and 
personal factors that drive overconsumption.6 
Macronutrient composition, energy density, and physical structure influence satiety.7 
Different amino acids, fatty acids, and carbohydrates have differing effects on the markers of 
appetite regulation.4 The differing effects imply that each nutrient interacts with the processes 
that mediate satiety in different ways.5 Dietary protein may promote weight loss by increasing 
energy expenditure and by inducing satiety.15, 27, 64, 65 Carbohydrates that are resistant to 
digestion, or which have a pronounced effect on glucose metabolism, have the potential to 
produce changes in appetite, and affect satiety. 66 Similarly, novel oils designed to reduce their 
absorption rate can potentially produce beneficial effects on appetite and satiety.6 The challenge 
lies in understanding which components of food interact optimally with the mediating processes 
to influence food intake. 
Protein 
High protein diets with their potential to act on metabolic targets regulating body weight, 
have become the subject of a body of research. Results from intervention studies suggest that an 
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increase in the relative protein content of the diet reduces the risk of positive energy balance and 
the progress to weight gain.67, 68 In short term studies (lasting for 24 hours up to five days), 
evaluating subjective satiety sensations, high protein diets have been shown to be more satiating 
than isoenergetic intakes of carbohydrate and fat.27, 64, 65 Contrary evidence is scarce.69 
Satiety mediated by protein is closely related to the increased energy expenditure 
accompanying protein intake. Protein-induced satiety is mainly due to the increase in the 
oxidation of amino acids ingested in excess. In respiratory chamber experiments satiety and 
thermogenesis increased with a high protein diet27, 65 and satiety was positively related to 24 hour 
diet induced thermogenesis.65 The modulation of glucose homeostasis and glucose signaling to 
the brain, precipitated by enhanced gluconeogenesis has been proposed as a mechanism for the 
satiating effect of protein. However, although gluconeogenesis increased with a high protein diet,  
there was no correlation between the appetite ratings and gluconeogenesis.70  
It has been hypothesized that protein induced satiety is related to increased concentrations 
of the anorexigenic hormones GLP-1 and PYY and a decrease in the orexigenic hormone 
ghrelin.27, 28 In a crossover trial,27 GLP-1 concentrations were measured nine times throughout 
the day, on the fourth day of consuming a high protein (30% of energy from protein) or adequate 
protein (10% of energy from protein) diet. After dinner, GLP-1 concentrations were significantly 
higher on the high protein diet as compared with the adequate protein diet. Energy expenditure, 
protein balance, and fat oxidation were also significantly higher on the high protein diet as 
compared with the adequate protein diet. Although ghrelin concentrations decreased, it could not 
be clearly attributed to the protein content of the diet, since the adequate protein diet with 
relatively high carbohydrate content also resulted in a decrease in ghrelin concentrations. 
Additionally, the increase in GLP-1 was related to the increase in satiety.27  
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In a three week crossover trial, an effect of protein consumption on PYY concentrations 
was demonstrated with significantly higher plasma PYY and greater satiety responses to a high 
protein meal in normal weight and obese individuals, as compared with isoenergetic high fat and 
high carbohydrate meals.28 However, in another study,64 there were no differences in ghrelin and 
PYY responses between a high protein (25% of energy) and average protein (10% of energy) 
diets. GLP-1 response was in fact lower following the high protein meal as compared with the 
average protein (but higher carbohydrate) meal.  
Specific amino acids may influence satiety by virtue of the fact that they are precursors 
for certain neurotransmitters involved in the regulation of appetite and body weight. Tryptophan 
is a precursor for the neurotransmitter serotonin, tyrosine can be converted into the 
neurotransmitters dopamine and norepinephrine and histadine can be converted into the 
neurotransmitter histamine. Each of these neurotransmitters has been linked with food intake 
regulation, although there is no direct evidence for their role in protein-induced satiety.15   
Milk and Eggs 
Milk and eggs are among the high protein foods often consumed as part of a breakfast 
meal. Dairy products have been shown to induce satiety and reduce food intake.71-73 
Additionally, dietary patterns that include increased consumption of milk have been associated 
with the prevention of body weight gain.74 The physiologic actions of the protein and calcium 
components of milk have been associated with regulatory effects on food intake and body 
weight.71, 75  
Casein and whey comprise 80% and 20% respectively of the protein in cow, sheep, goat, 
and buffalo milk.76 Whey protein has been found to be more satiating in some studies,77, 78 while 
other studies have found no difference in the satiating effects of whey and casein proteins75, 79 or 
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that casein protein leads to a greater satiating effect than whey protein.80 However, the effect of 
protein source is modulated by several factors including dose, form (solid or liquid), time to the 
next meal, and the presence or absence of other macronutrients.76  Nevertheless, energy intake 
was 9% lower after intake of milk than after intake of casein or whey.75 Thus, complete milk 
proteins might elicit an intermediate yet optimal satiating effect, or other bioactive components 
in milk influence its satiating power.  
Satiety has been reported after consumption of dairy foods. Chocolate milk and a 
carbonated soft drink were matched for energy density and energy content, in a study to compare 
the satiety effects of the two beverages. Increased short term satiety was observed after 
consumption of chocolate milk as compared with the soft drink, but did not affect the ad libitum 
energy consumption at lunch served 30 minutes later.72 The addition of 600 ml of skim milk to a 
fixed energy breakfast induced greater satiety than a fruit drink, and reduced energy intake at a 
buffet sandwich meal four hours later.73  
Very few studies have assessed the impact of calcium consumption alone on the 
regulation of food intake. In women consuming < 800 mg/day of calcium, daily supplementation 
of calcium + vitamin D (1200 mg calcium + 10 µg vitamin D) for 15 weeks, reduced fat and total 
energy intake at an ad libitum food intake test.81 Subjects participating in a six month energy 
restriction program were assigned to either milk (1000 mg of calcium) or placebo (0 mg calcium) 
supplemented groups. Milk supplementation resulted in an increase in measured fullness that 
was significantly different from the decrease predicted by weight loss. Additionally, weight loss 
was found to induce orexigenic effects that were attenuated in the group receiving the milk 
supplementation.71 However, milk supplementation led to an increase in protein intake; hence, it 
was difficult to distinguish between the effects of protein and calcium on food intake regulation.  
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The protein content of eggs is 35% of their total energy content.82 Isoenergetic egg (23% 
of energy from protein) and bagel (16% of energy from protein) breakfast meals were compared. 
The egg breakfast significantly reduced the insulin, glucose, and ghrelin concentrations. 
Additionally, hunger was reduced and satisfaction increased after the egg breakfast as compared 
with the bagel breakfast, resulting in a reduction in food intake at a subsequent meal.83 In another 
study comparing isoenergetic egg (18.3 g protein) and bagel (13.5 g protein) breakfasts, matched 
for weight, the egg breakfast resulted in an increase in satiety and a reduction in energy intake at 
lunch. There was no compensation for the reduction in energy intake in the 24 hour period 
following breakfast, as assessed by self-reported food intake.84 No difference in energy intake 
was found at dinner following consumption of three isoenergetic test lunches: omelet, jacket 
potato, and chicken sandwich, although the omelet meal was found to elicit a higher satiety 
response than the potato and chicken meals.82 
Carbohydrates 
Carbohydrates influence satiety through multiple mechanisms related to their hormonal 
effects,  intrinsic properties, and intestinal fermentation.85-90 The hormonal effects of 
carbohydrates on satiety are mediated by insulin90 and gastrointestinal hormones.88, 89  Intrinsic 
properties include the bulking and viscosity effects of dietary fiber.85, 87 Carbohydrates that evade 
small intestinal digestion, enter the large bowel and are fermented by colonic bacteria into short 
chain fatty acids which have been shown to enhance satiety.86  
The potential physiologic mechanisms relating the Gi to the regulation of food intake are 
based on the postprandial metabolic milieu precipitated by hyperglycemia and hyperinsulinemia. 
It has been suggested that a high glycemic load (product of Gi  and available carbohydrate 
content)  meal elicits a high insulin and low glucagon response that promotes uptake of glucose 
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in muscle, liver, and fat tissue, thereby restraining hepatic glucose production and inhibiting 
lipolysis.90 Limited access to the two major metabolic fuels in the post-absorptive state, may lead 
to a quick hunger response and overeating, in the body’s attempt to restore the concentration of 
metabolic fuels to normal.90 Low Gi foods are characterized by a slow rate of digestion and 
absorption, thereby eliciting a low glycemic response.91  
A majority of studies reviewed support an increased short term satiety with low Gi foods 
or meals compared with high Gi foods or meals.17 A systematic review of the effect of low Gi 
diets on satiety and body weight in the long term (several days or weeks duration) found 
inconsistent results.18 The clinical relevance of diets based on the Gi remains unclear. A large 
part of the debate appears to center around inconsistencies in the data. The Gi is influenced by 
the nature of the starch, the physical form, the amount of fiber, fat and protein, and the cooking 
times and methods.92 Other dietary factors affecting food digestibility, gastrointestinal motility, 
or insulin secretion also determine the Gi of a food.93 The Gi relates to a food and not the 
individual; therefore, there exists the possibility of intra- and inter- individual variances in the 
Gi. The random day-to-day variation in the glycemic response that occurs even in repeated 
experiments of the same food under standardized conditions is seemingly inexplicable.94 
Dietary fiber may be classified into soluble and insoluble fiber on the basis of water 
solubility. Colonic fermentation of soluble fiber yields short-chain fatty acids. Insoluble fiber 
generally has low fermentability, but it has water-attracting properties that promote fecal bulk.95 
 Several mechanisms have been proposed to explain the effects of dietary fiber on the 
regulation of appetite, and satiety: (1) Dietary fiber traps nutrients and retards their passage 
through the GI tract, enhancing the interaction between the intestinal wall and nutrients. 
Exposure of the intestinal mucosa to nutrients stimulates the release of appetite regulating 
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peptides which function as hormones, or activate neural pathways involved in appetite 
regulation.29 (2) Energy density is inversely associated with  satiety.33  Dietary fiber lowers the 
energy density of a food34 and by implication enhances satiety. (3) Fiber increases mastication, 
and it requires time and effort to eat the fiber-containing food.  Additionally fiber limits intake 
by stimulating the secretion of saliva and gastric secretions that cause stomach distension, 
thereby promoting satiety.16 (4) Lastly, although colonic fermentation of undigested 
carbohydrate to short chain fatty acids has been hypothesized to increase satiety, data from 
human intervention studies do not appear to support a role for intestinal fermentation in appetite 
regulation.19-21 
Consumption of highly viscous soluble dietary fiber delays gastric emptying which can 
increase stomach distension30 thereby stimulating afferent vagal signals of fullness.4 While 
gastric satiety is mechanical in origin, intestinal satiety is nutrient-dependent, nevertheless, there 
exists evidence for a synergy of the two types of stimulation.31, 96 Satiety signals are released 
following interaction between the gut wall and nutrients. In the small intestine, the increased 
viscosity of contents prolongs transit time and reduces the absorption rate of nutrients, thereby 
enhancing the possibility of interaction between nutrients and the cells that release satiety 
hormones.29 Although hunger and satiety sensations originate in the central nervous system, gut 
hormones play a key role in the regulation of food intake.97 
Whole-grain products are good sources of dietary fiber. The 2010 Dietary Guidelines for 
Americans recommend that at the 2000 kcal level, grain products should comprise six servings 
of which at least three servings should come from whole-grains.98 In the US, total grains servings 
are typically over-consumed; however, most Americans are not consuming adequate amounts of 
whole grains.99 From an analysis of NHANES data from 1999 – 2004 it was determined that 
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mean whole grain consumption among adults aged 19-50 years, and 51 years and over was 0.63 
and 0.77 servings/day respectively. Less 5% of adults in the age group 19 -50 years consumed 
the recommended servings of whole grains.100 There appears to be evidence to indicate that since 
the 2005 Dietary Guidelines for Americans, consumers have increased purchases of whole-
grains, especially cereals, breads, and pasta. Competition among manufacturers leading to more 
products with whole grains being made available, may have triggered the increase in 
consumption.101  
Breads and Breakfast Cereals 
 Ready-to-eat cereals (28.7%) yeast breads (25.3%) and hot cereals (13.7%) are the major 
sources of whole-grain consumption in the US;102 and they have been shown to enhance 
satiety.87, 103-106  However, not all whole-grain breads increased satiety. In a comparison of 
whole-grain wheat bread and refined grain wheat bread, subjective satiety and food intake 
following consumption of the whole-grain bread providing 10.5 g of fiber per day for three 
weeks was not significantly different as compared with refined grain bread providing 5.8 g of 
fiber per day.107 Yeast breads contribute 26% to non-whole grain consumption102 and enriched 
and fortified grains provide important nutrients, especially folate.99 The addition of fiber 
components to refined grain flours used in the production of breads and breakfast cereals has 
also been found to have beneficial effects on the regulation of appetite.89, 108 Thus, it is important 
to encourage consumption of both enriched grains as well as whole grains in the recommended 
proportion. 
Although rye is not among the grains commonly consumed in the US,109 it is a good 
source of soluble and insoluble dietary fiber.110 The main fiber components of the cell wall in rye 
are arabinoxylan, ß-glucan, and cellulose. Arabinoxylan is the dominant fiber, and the water 
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extractable component of arabinoxylan exhibits a high viscosity when dispersed in water.111  
While ß-glucan is susceptible to degradation, arabinoxylan is resistant to the bread making 
process and retains its average molecular weight.110 The molecular weights of the individual 
fiber types affect their physiologic properties, including viscosity. 
Rye flour is usually made from a blend of different rye varieties. Several whole grain rye 
breads made with different rye varieties, including a commercial blend of rye varieties, were 
compared with bread made from refined wheat flour. Subjective satiety was significantly higher 
following consumption of the commercial blend which had the highest insoluble fiber content 
(10.3 g) as compared with the wheat bread (2.4 g insoluble fiber). However, not all varieties of 
rye increased satiety.103, 104  
In an assessment of a dose-response relationship it was found that while rye bread (60% 
rye bran flour, 40% wheat flour) with 5 g or 8 g of fiber served as part of  isoenergetic breakfasts 
increased satiety as compared with a wheat bread breakfast, there was no significant difference 
in satiety between the two rye bread breakfasts.112 Varying the structure of rye flour (whole rye 
kernels or milled rye kernels) used to make bread did not result in different effects on satiety.113  
Rye porridge and rye bread made from different parts of the rye grain (endosperm, 
whole-grain, and bran) were compared with bread made from refined wheat. It was found that 
the porridge made from whole-grain and bran fractions, elicited an increase in satiety as 
compared with the bread made from the same parts of the grain, however all rye products 
increased satiety as compared with wheat bread.114 The same investigators also compared the 
effects of similar rye breads on appetite and satiety, with meals made by boiling rye kernels.  
Consumption of rye kernel meal was not only found to be more satiating than the breads, but it 
also reduced food intake at a subsequent meal.115  
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Whole grain rye porridge breakfast (followed by whole grain wheat pasta lunch or 
refined wheat pasta lunch) and refined wheat bread breakfast (followed by refined wheat pasta 
lunch) were compared. The meals were matched for macronutrient content. Satiety ratings were 
significantly higher after the rye porridge breakfast when compared with the refined wheat bread 
breakfast. Following consumption of the refined wheat pasta lunch meal subjects who ate the rye 
porridge breakfast meal continued to have greater sensations of satiety as compared with those 
who ate the refined wheat bread breakfast meal.116 In another study, whole-grain rye porridge 
increased satiety as compared with an isoenergetic refined wheat breakfast. Although the effect 
on satiety was sustained during three weeks of regular intake, it was only maintained up to four 
hours and energy intake at subsequent meals were not significantly different.117 
Lupin-kernel flour, derived from the endosperm of lupin seeds, contains 40-45% protein 
and 25-30% fiber with negligible amounts of sugar and starch.108  A lupin-kernel fiber-enriched 
sausage patty was shown to produce greater effects on satiety than both a conventional patty and 
an inulin fiber-enriched patty.118 Partial substitution of lupin-kernel flour for wheat flour in 
bread-making increases the protein and fiber content of bread. Bread made by a substitution of 
40% of wheat flour with lupin-kernel flour was compared with bread made with 100% wheat 
flour. Served as isoenergetic breakfasts with margarine and jam, the lupin-kernel fiber bread 
resulted in greater satiety and lower energy intake at lunch when compared with the wheat 
bread.108  
β-glucan, found in significant amounts in oat and barley, exhibits a high viscosity at 
relatively low concentrations.119 The satiating effect of ß-glucan has been demonstrated in 
several studies using ß-glucan in doses ranging from 2.2 g to 9 g. 85, 88, 89, 120-122  Other studies 
found no effect of ß-glucan on satiety.123-125  Bread made with 100% wheat flour was compared 
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with bread in which 4.5% of the wheat flour was replaced with 3 g of concentrated extract of 
barley ß-glucan, a viscous soluble fiber. The bread containing barley ß-glucan increased satiety 
and reduced food intake at a subsequent meal by 19% as compared with the bread made with 
100% wheat flour.89 In contrast, inclusion of barley ß-glucan into breakfast and lunch meals 
(including barley cereal at breakfast and barley bread at lunch) did not increase satiety as 
compared with wheat-containing meals (including bran flakes at breakfast and refined wheat 
bread at lunch) with similar energy and nutrient contents. Barley-containing meals were in fact 
associated with higher energy intake during the remainder of the day, assessed through self-
reported food records.126 However, self-reported data are notorious for their susceptibility to 
misreporting and altered feeding behavior.127 
Regular consumption of breakfast cereals, as assessed through food frequency 
questionnaires has been associated with a lower body mass index, and reduced likelihood of 
being overweight.128 Crushed or rolled oats are often used in the production of breakfast 
cereals.119 The content of β-glucan in commercial grade oats in North America varies from 35-50 
g/kg.129 Variations in the source, processing treatments, manufacture of a product, and the 
interactions with other constituents in the food matrix affect the amount, solubility, molecular 
weight, and structure of the β-glucan in the products.130 Thus, the functionality of β-glucan 
differs from one product to another.  
Viscosity is controlled by concentration in solution and molecular weight.131 Oat β-
glucan is more soluble in hot water than in water at room temperature, so processing steps that 
involve moisture and heat will in all likelihood increase the solubility of β-glucan.132 Cooking of 
oats has been shown to increase the percentage of β-glucan solubilized by three-fold.49 β-glucan 
is integral with cellulose and other noncellulosic polysaccharides in the cell wall and cooking 
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releases it from this matrix.133 Thus, food structure and matrix of the product delivering the β-
glucan affects its bioavailability.130  
Breakfast cereals containing oat ß-glucan in amounts ranging from 2.2 g to 5.7 g and a 
corn-based breakfast cereal (0 g ß-glucan) were compared. The breakfasts were isoenergetic. 
Subjective satiety increased with each of the breakfast meals containing oat ß-glucan as 
compared with the corn-based breakfast meal. However, there was no difference in the overall 
satiety responses between the breakfasts containing oat ß-glucan.85 In a separate study, the same 
investigators, examined the effects of varying the dose of oat ß-glucan from 2.2 g to 5.5 g 
delivered through breakfast cereals, and concluded that the optimal dose of β-glucan affecting 
satiety and other markers of appetite regulation were between 4 g and 6 g and that the hormonal 
effects were mediated through increased viscosity. Increasing the dose of β-glucan resulted in a 
greater release of PYY.88  
Other studies have shown that ß-glucan had no effect on satiety.  Muesli containing 4 g of 
oat ß-glucan served in yogurt, did not result in a significantly prolonged period of satiety as 
compared with an isoenergetic meal consisting of cornflakes served in yogurt.123 Satiety ratings 
were compared following ingestion of wheat bran flakes (7.5 g fiber), whole-meal oat flakes (4 g 
fiber: 0.5 g ß-glucan), and cornflakes (1.5 g fiber) of equal weight served with milk. Bran flakes 
or oat flakes did not result in significantly higher satiety when compared with corn flakes.124  
In a study investigating the satiating effects of barley ß-glucan, hunger was found to be 
lower with barley products (9 g β-glucan) as compared with whole wheat, and rice products 
served at breakfast as a hot cereal, and at mid-morning as a snack mix.122 In other studies 1.2 g 
barley β-glucan in a meal replacement bar,19 had no effect on satiety and 2 g of barley β-glucan 
served in a hot cereal did not affect short term satiety in overweight individuals.134    
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The insoluble fiber found in breakfast cereals made with whole-grain wheat has also been 
demonstrated to increase satiety as compared with cornflakes of equal weight,87 or equal energy 
content,105 however, the amounts of insoluble fiber ranged from 26-33 g/meal.87, 105 In a 
comparison of isoenergetic breakfasts, increased fullness was observed with a meal high in 
insoluble fiber (whole grain wheat bran breakfast cereal: 18.1 g fiber) as compared with a 
breakfast of bacon and eggs,106 which was higher in fat and comparable in protein. Additionally, 
the total fiber content of a food by lowering its energy density affects satiety as energy density 
and satiety are inversely associated.33    
Fat 
Fats have been shown to reduce hunger when present in the GI tract by eliciting satiety 
signals.22 Fat in the  duodenum stimulates the release of cholecystokinin and other 
gastrointestinal peptides that affect satiety.31 Exposure of the ileum to fat stimulates an even 
larger satiety response than exposure to the duodenum.35 Fat reaching the ileum stimulates the 
ileal brake, a distal to proximal feedback mechanism that controls the transit of food through the 
GI tract. Nutrients in the small intestine, influence satiety and food intake by activation of neural 
afferents or by stimulating the release of gut hormones involved in appetite regulation.31, 135 
 Bariatric surgery is arguably the most effective weight loss treatment for the morbidly 
obese.136 The Roux-en-Y gastric bypass surgery results in a speedy delivery of nutrients to the 
distal parts of the GI tract. Meal-stimulated increases in PYY and GLP-1, gut hormones with 
anorectic effects, implicated in the ileal brake activation, have been observed after the Roux-en-
Y gastric bypass.136, 137 Thus, bariatric surgery provides evidence that a sustained appetite 
reducing effect is possible through a recurring activation of the ileal brake.35  
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Infusion of triglycerides into the ileum has been shown to alter duodenal motility and 
delay gastric emptying.138 Ileal fat infusion has also been shown to cause a dose-dependent delay 
in gastric emptying and has been related to increased plasma concentrations of PYY.36 37 An ileal 
infusion of corn oil increased feelings of satiety and reduced ad libitum food intake at a meal 30 
minutes after the start of the infusion. However, the rate of infusion of fat can be compared to 
what one may find in normal subjects after eating a heavy meal.38, 39 Nevertheless, a low 
physiologic dose of fat (6 g) into the ileum elicited a significant reduction in hunger and food 
intake when compared with an oral ingestion of the same amount of fat.139 A pooled analysis of 
studies investigating the effects of fat on gastric emptying and GI hormone release determined 
that the magnitude of stimulation of pyloric pressures and release of cholecystokinin, a hormone 
with anorexigenic effects, are independent predictors of subsequent energy intake.140 
The physicochemical properties of fat affect its ability to regulate GI motor function, gut 
hormone release, and satiety.  These effects are more pronounced with LCT (>12 carbons) than 
shorter chain fatty acids.22, 40, 41 A 180 kcal duodenal infusion of long chain fat emulsions 
reduced food intake by over 200 kcal as compared with a saline infusion.40 Duodenal infusion of 
12 carbon fatty acids reduced appetite and energy intake at a subsequent meal as compared with 
10 carbon fatty acids. The effects on gastroduodenal motility that were observed are typically 
associated with delayed gastric emptying.41 Hunger and gastric emptying are closely related. It 
has been suggested that accelerated gastric emptying decreases gastric distension, thereby 
promoting hunger.141 The effects of fat on gastric emptying are however, dependent on digestion 
of fats and consequent release of free fatty acids.141  
Medium chain triglycerides (MCT) (6-12 carbons) have been shown to influence satiety 
through increased energy expenditure.42 Unlike LCT, MCT are directly absorbed into portal 
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circulation and are more rapidly metabolized. The role played by the degree of saturation in 
modulating the effects of fat on the GI tract has not been resolved fully.43, 44 
Novel Oils 
Pinnothin™ is a natural oil pressed from Korean pine nuts and contains linoleic acid 
(C18:2), pinolenic acid (C18:3), and oleic acid (C18:1). Consumption of Pinnothin™ 
triglycerides and free fatty acids has been shown to produce an increase in cholecystokinin and 
GLP-1 in post-menopausal overweight women. However, appetite ratings did not significantly 
differ in comparison with olive oil.142 In overweight women, appetite ratings were not 
significantly different after consumption of Pinnothin™ triglycerides or free fatty acids as 
compared with olive oil, although Pinnothin™ free fatty acids reduced food intake by 7% at a 
subsequent meal.143 In both the studies142, 143 participants consumed Pinnothin™ in capsule form. 
When Pinnothin™ triglycerides were added to a yogurt, appetite sensations  and energy intake 
were not significantly different as compared with milk fat.144 
Delaying lipid digestion is an important factor in stimulating the ileal brake. The 
digestion of fat can be slowed down by manipulating the oil emulsion interfacial composition 
using galactolipids. It has been shown that galactolipids reduce the rate and extent of lipolysis by 
sterically hindering the penetration of pancreatic colipase and lipase at the oil-water interface in 
the duodenum.145 Olibra™ is a fat emulsion comprised of fractionated palm, and oat oil in the 
proportion of 95:5. The palm oil is emulsified by hydrophilic galactolipids derived from oat 
oil.146   
Early studies23-25 all using crossover designs, reported a reduction in energy, 
macronutrient and total weight of food intake, following consumption of yogurt containing the 
Olibra™ emulsion. The suppressive effects on appetite ratings (hunger, desire to eat, and 
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preoccupation with thoughts of food or perceived fullness) were only demonstrated in one 
study24 and one part of another study.23 The effects were evident four hours23 after consumption 
of the test product, were maintained at least until eight hours, and were evident in non-
overweight, overweight and obese subjects.24 Using self-reported food intake data, it was 
concluded that the treatment effects of Olibra™ were maintained up to 36 hours.25 Additionally, 
the effects of Olibra™ were shown to be dose dependent but results were not consistent across 
gender or proportional across dose levels. Lower mean energy (21%, 25%, and 30% with 2g, 4g, 
and 6 g of Olibra™, respectively) macronutrient, and total weight of food, intake were observed 
after consumption of the test product, as compared with a placebo.25 
Subsequent studies investigating Olibra™ failed to confirm the reduction in energy 
intake.45-47 In one study with a crossover design wherein each subject was studied for a period of 
nine weeks (two, three-week intervention phases that were separated by a three-week period) no 
treatment effect for energy, macronutrient, or total weight of food, intake was observed four 
hours after consuming the test product as assessed by a food intake test, or during the remainder 
of day and on the post-test day based on self-reported food records.45 Ratings of hunger, fullness, 
desire to eat, prospective consumption or preoccupation with thoughts of food did not reflect any 
treatment effects of Olibra™.45  However, in another study a suppressive effect over appetite 
ratings at three hours, and a lower return to baseline hunger in normal weight women aged 
between 18 and 30 years was observed which did not translate into a reduction in food intake.46  
A meta-analysis147 of the short term effects of Olibra™ on food intake, indicated that 
Olibra™ may suppress appetite more effectively at doses that are less than 5 g. No relationships 
were found between the appetite suppressant effects of Olibra™ and sex, age, or BMI.  The 
divergent results from various studies were attributed in part to the manufacture, processing, or 
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preparation of Olibra™. It has been speculated that the functional integrity of the Olibra™ 
emulsion structure is affected when it is subjected to processing such as homogenization and 
pasteurization, along with the yogurt used in most studies as the vehicle for delivering Olibra™. 
The emulsion is susceptible to breakdown when exposed to thermal and shear processing and to 
an acidic environment.147 Although the unprocessed emulsion, and not the processed form 
produced a modest decrease in food intake measured eight hours following consumption, there 
was no effect on appetite and satiety ratings.148 More recently, Fabuless™ (also known as 
Olibra™) added to yogurt beverages exposed to minimal processing had no effect on satiety or 
food intake.48 
The beneficial effects of Olibra™ on body composition and weight maintenance after 
weight loss have been demonstrated.149 In the weight maintenance phase following weight loss 
as a result of a very low calorie diet, there was no significant increase in body weight, BMI, and 
waist circumference in the group consuming Olibra™ for 18 weeks, whereas the control group 
showed a significant increase. Additionally, there was a significant decrease in fat mass and an 
increase in lean body mass in the test group as compared with the control group.149 However, in 
another study the addition of Olibra™ to a meal replacement diet plan following weight loss, 
resulted in a 0.9% decrease in body fat mass but caused no change in body weight at the end of 
12 weeks.150 
In these studies, the energy restriction imposed during the weight loss period may have 
had a role to play in the beneficial effects. In humans, it has been shown that exposure to a high 
fat or high energy diet decreases sensitivity to the GI mechanisms involved in appetite 
regulation.22, 141, 151  It has been suggested that dietary restriction may reverse these effects 
resulting in enhanced nutrient sensing and exacerbation of appetite suppression.22 A high fat diet 
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(58% of energy intake) for two weeks has been shown to modify appetite perceptions, increasing 
hunger and decreasing fullness. A significant increase in energy intake of approximately 
160kcal/day was observed for the following two week period.152 Placing subjects on a high fat 
diet derived from sunflower oil for only three days resulted in an acceleration of gastric 
emptying.151 However, a delay in GI transit and a reduction in satiety following a high fat diet 
shown to occur over a one week period was found to return to pre-diet levels by the end of four 
weeks.151 
A 45 minute delay in intestinal transit time following consumption of Fabuless™  has 
been reported.30 However, the methodology for computation of orocecal transit time by 
measuring sulfapyridine, a colonic metabolite of salazopyrine has been questioned.41 Following 
an intragastric administration of Fabuless™ a significantly higher amount of total lipids and the 
occurrence of crystals was observed in the jejunal samples as compared with an intragastric 
administration of milk fat. The authors suggested that the formation of palmitic acid crystals led 
to the gradual release of free palmitic acid as the crystals are transported further down the 
intestine into the ileum. Exposure of the ileum to unabsorbed lipids stimulated the activation of 
the ileal brake mechanism.146  
While it is important to demonstrate that Olibra™ produces conditions conducive to 
stimulation of the ileal brake mechanism, such manipulation must also produce the directional 
changes in feeding behavior consistent with the activation of this mechanism. Eating behavior 
comprises a large learned and anticipatory component.127  Behavioral and environmental factors 
can overcome physiological drives and influence feeding behavior.153 Therefore, a physiologic 
impetus would have to be sufficiently large to consistently correlate with altered energy and 
nutrient intakes.  
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Journal Articles 
Two articles are presented in this thesis. The article reporting the effects of a novel fat 
emulsion, Olibra™, on satiety, food intake, and body weight has been published in the Journal of 
Diabetes Science and Technology (2012;6(3):695-708). This article also reviewed the published 
human studies that investigated the effects of Olibra™. The article reporting the short term 
effects of oatmeal on appetite and satiety as compared with a RTEC will be submitted to The 
American Journal of Clinical Nutrition. 
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CHAPTER 3 
EFFECT OF OATMEAL ON APPETITE AND SATIETY WHEN 
COMPARED TO A READY-TO-EAT BREAKFAST CEREAL 
 
Introduction 
Obesity, caused by a chronic energy imbalance is a multifaceted problem with complex 
contributing factors, including genetics, hormone levels,55 behavioral patterns, and their 
environmental determinants.56 The decision to eat often arises as a consequence of appetite as 
opposed to the need for energy, and meal initiation is therefore non-homeostatic.57  Thus, 
appetite and satiety become important elements in the adjustment of energy intake to 
expenditure. Appetite sensations influence the search, choice, and ingestion of food.4  Satiety 
refers to a subjective feeling of the absence of the motivation to eat, decline in hunger, and 
increase in fullness after a meal is eaten.7 Appetite sensations and satiety have been shown to be 
good predictors of energy intake.9, 10  Although weight loss is complex and difficult, enhancing 
satiety is a legitimate means of facilitating the process especially if the proposed food is 
consumed regularly as part of a culturally accepted eating pattern such as breakfast. 
Macronutrient content can influence the satiating power of a food.7 Relatively more 
protein in a particular meal results in relatively elevated amino acids, anorexigenic hormones, or 
the activation of energy expenditure feedback mechanisms on the central nervous system.15 The 
satiating effect of carbohydrates is determined by the type and form of carbohydrate. It has been 
hypothesized that foods with a high glycemic index (Gi) elicit a higher immediate insulinemic 
response. The ensuing hypoglycemic period increases hunger and lowers satiety as compared 
with a lower Gi food.90 Dietary fiber through its bulking and viscosity effects poses a 
physiological obstacle to energy intake. Consumption of highly viscous soluble dietary fiber 
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delays gastric emptying which can increase stomach distension,30 and thereby stimulates afferent 
vagal signals of fullness.4  
Gastric satiation is volume-dependent and intestinal satiety is nutrient-dependent, yet, 
there is evidence for a synergy of the two types of stimulation.31, 96 Satiety signals are released 
following interaction between the gut wall and nutrients. In the small intestine, the increased 
viscosity of contents prolongs transit time and reduces the absorption rate of nutrients.35 
Although hunger and satiety sensations originate in the central nervous system, gut hormones 
play a key role in the regulation of food intake.97 
Crushed or rolled oats are often used in the production of breakfast cereals. β-glucan, a 
soluble fiber found in significant amounts in oat kernels exhibits a high viscosity at relatively 
low concentrations.119 The content of β-glucan in commercial grade oats in North America varies 
from 35-50 g/kg.129 Variations in the source, processing treatments, manufacture of a product, 
and the interactions with other constituents in the food matrix affect the amount, solubility, 
molecular weight, and structure of the β-glucan in the products.130 Thus, the functionality of β-
glucan differs from one product to another.  
The satiety effect of an oatmeal breakfast was compared with the most widely sold ready-
to-eat breakfast cereal (RTEC) in the United States (based on IRI Liquid Data, 52 Weeks Ending 
March 11, 2012). It was hypothesized that the oatmeal breakfast with a higher content of fiber 
would result in greater satiety than the oat-based RTEC, over the four hour period following 
consumption. 
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Subjects and Methods  
Subjects 
Forty-eight healthy subjects 18 years of age or older, were enrolled in a randomized, 
crossover trial. All subjects participated in an initial screening that involved measurement of 
body weight, height, waist and hip circumferences, vital signs (blood pressure, pulse rate), 
chemistry-15 panel, complete blood count with differential,  and β-HCG pregnancy test-urine (in 
females of child-bearing potential).  Questionnaires related to dietary restraint (Eating 
Inventory)154 which have been used extensively to measure individual variability in eating 
behavior,155 were completed to exclude restrained eaters. Female subjects also completed a 
menstrual cycle questionnaire so that breakfast test days would fall within the luteal phase of the 
menstrual cycle.156 In addition to the laboratory tests and measurements of vital signs, a medical 
screening questionnaire was used to confirm health. Exclusion criteria were: (i) women who 
were pregnant or nursing, (ii) self-reported weight gain or loss of 4kg or more in the last 3 
months, (iii) fasting glucose >126mg/dL, (iv) dietary restraint score ≥ 14, and (v) allergy or 
intolerance to oats or milk. 
The study was approved by the Institutional Review Board of the Pennington Biomedical 
Research Center and participants provided written informed consent. The trial was registered on 
ClinicaTrials.gov with registration number NCT01372683. 
Study Design 
Each participant was tested on two days. On one occasion the breakfast meal consisted of 
Quaker Old Fashioned Oatmeal™ and on the other occasion the breakfast meal served was the 
RTEC, Honey Nut Cheerios™. Order of the two breakfasts was randomly assigned. The 
breakfasts contained 355 kcals, consisting of 250 kcals of cereal, and 105 kcals of lactose-free, 
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fat-free milk. A nutrient analysis of both breakfasts is presented in Table 3.1.  The oatmeal (66.8 
g dry weight), was cooked in a microwave at high power for three minutes with 355.5 g of water, 
allowed to stand for a minute, and served with 307 g of milk. The RTEC (63.6 g dry weight), 
was prepared by adding 307 g of milk, and served with 355.5 g of water. The participants had the 
option of adding 1 g of Splenda™ and one-half teaspoon of cinnamon to the oatmeal. If the 
participant added Splenda™ and cinnamon to the oatmeal, they were required to add both, in the 
same amounts to the RTEC. 
At the first test breakfast visit, participants arrived at the center after a 10 hour overnight 
fast, and having avoided strenuous exercise for 24 hours prior to the test meal. They completed a 
questionnaire about colds or allergies that might affect taste, and were asked to return on another 
day if such a condition was present.  Electronic visual analog scales (VAS),7, 62 were 
administered prior to serving the test meal. Participants rated each subjective state by placing the 
cursor over a line on a computer screen and clicking at a point, which was anchored using the 
descriptors “Not at all” to “Extremely.”  Visual analog scales were scored by the computer on a 0 
to 100 millimeter (mm) scale and the score was sent directly to the database. Hunger, fullness, 
desire to eat, and prospective intake, were assessed. Satisfaction with the meal which introduces 
a hedonic component into the measurement of satiety,63 was included to determine if satiety 
measures were judged from a comparable baseline during the repeated testing. 
The subjects were presented with their first breakfast test, and given 20 minutes to eat it. 
Test meals were supervised to ensure that the entire breakfast was eaten. Visual analog scales 
were then administered at 30, 60, 120, 180, and 240 minutes following the start of the breakfast 
meal.  Subjects were asked an open ended question, “How do you feel?” at each of the time 
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points that the VAS were completed to elicit any adverse events. Subjects returned on another 
day separated by at least a week to repeat the breakfast test.   
Table 3.1 Energy and nutrient content of  breakfast meals which included the 
breakfast cereal and lactose-free, fat-free milk  
  
Quaker 
Oatmeal1 Honey Nut Cheerios2 
Lactose-Free, Fat-Free 
Milk 
Kilocalories (kcal) 250 250 105 
Fat (g) 5.01 3.41 0.25 
Protein (g) 8.35 4.54 10.33 
Carbohydrates (g) 45.09 49.97 15.6 
Fiber (g) 6.68 4.54 0 
Soluble Fiber (g) 3.34 1.70 0 
β-Glucan (g) 2.28 1.67 0 
Sugar (g) 1.67 20.44 0 
  
      
Serving Size (g) 66.8 63.6 306.3 
1Quaker Oats; (Pepsico Inc. Barrington IL); 
2Honey Nut Cheerios; (General Mills Inc. Minneapolis MN) 
 
Statistical Analysis 
A mixed model ANOVA for a 2 x 2 crossover trial was performed to analyze the primary 
outcomes. Visual analog scale scores for hunger, fullness, desire to eat, prospective food intake, 
and satisfaction with the meal were analyzed in terms of the area under the curve (AUC). The 
model included fixed effects (residual treatment carryover effects from test day 1 to test day 2 
[treatment sequence effects], test day main effects, and treatment main effects), and random 
effects (subjects within treatment sequence groups). The secondary outcomes, were changes in 
VAS for hunger, fullness, desire to eat, prospective intake, and satisfaction from time 0 to 30, 60, 
120, 180, and 240 minutes following the start of the breakfast meal. Secondary outcomes were 
analyzed using a mixed model ANOVA for a doubly repeated measures crossover trial where the 
first repeated measures variable was test day, and the second variable was time since start of 
breakfast. The changes from time zero were summarized as least squares means plotted for each 
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cereal type across the assessment times. Thus, differential treatment effects were compared with 
respect to AUC, and per time point using SAS (version 9.2, 2002-2008, PROC MIXED; SAS 
Institute, Cary, NC). Area under the curve was estimated using the linear trapezoidal rule and 
calculated as the area between the zero change line and the measured change curve which could 
be either above or below the zero change line. 
During the planning phase of the study, sample size was estimated using G*Power, 
Version 3.1.2 (F. Faul, Universitat Kiel, Germany) with the following assumptions: (i) power ≥ 
0.78 was considered acceptable, (ii) the significance level under the null hypothesis was set at 
α=0.05, (iii) the primary outcome was VAS AUC with a priori standard deviation assumed to be 
3047mm×min based on previous research142 and (iv) the null hypothesis was to be tested against 
a two-directional alternative. The study was sufficiently powered with 46 participants for 
detecting a minimum difference of 1258 mm×min between cereal types, which is similar to 
observed differences in AUC (1213 mm×min) for desire to eat from a similar food intake 
study.142 
Results 
Forty eight subjects were enrolled in the study. Two subjects who were unable to 
complete the study withdrew. Data related to 46 subjects were analyzed.  There were no adverse 
events. Descriptive characteristics of the subjects at baseline are summarized in Table 3.2.  
 
 
 
 
 
  
36 
 
Table 3.2 Subject Characteristics at baseline 
including age, body mass index, waist 
circumference, gender, and race 
  n = 46 
  Mean ± SD 
Age  34.1 ± 14.3 
BMI (kg/m2) 26.1 ± 7.2 
Waist Circumference (cm) 82.2 ± 15.5 
  n (%) 
Gender 
Female 29 (63) 
Male 17 (37) 
Race 
American Indian 1 (2.2) 
Asian 2 (4.3) 
Black 16 (34.8) 
White 27 (58.7) 
 
Hunger 
The reduction in hunger was significantly greater after consuming oatmeal as compared 
with the RTEC (p=0.0009) based on the AUC (oatmeal: 12,372±817.96 mm×min versus RTEC: 
9,656±817.96 mm×min), and the least squares means (Figure 3.1) at 120min (p=0.0197), 180min 
(p=0.0003), and 240min (p= 0.0036) following consumption of the breakfast meals.  
Fullness and Satisfaction 
Increase in the sensation of fullness was significantly greater after consuming oatmeal as 
compared with the RTEC (p=0.005) based on the AUC (Oatmeal: 13,392±740.57 mm×min 
versus RTEC: 11,233±740.57 mm×min) and the least squares means (Figure 3.2) at 120min 
(p=0.0408), 180min (p=0.0061), and 240 min (p=0.0102). The response to how satisfied subjects 
felt, was not significantly different between the two breakfast meals, except for greater 
satisfaction after consuming oatmeal at 180min (p=0.0392) as depicted in Figure 3.3. 
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Desire To Eat and Prospective Intake 
Reduction in the desire to eat was significantly greater after consuming oatmeal as 
compared with the RTEC p=0.0002), based on the AUC (oatmeal: 13,188±804.53 mm×min 
versus RTEC: 10,425±804.53 mm×min) and the least squares means (Figure 3.4) at 120min 
(p=0.0168), 180min (p<0.0001), and 240min (p=0.0022). Reduction in subjects’ perceptions of 
prospective food intake, was significantly greater after consuming oatmeal as compared with the 
RTEC (p=0.0012), based on the AUC (oatmeal: 10,360±823.67 mm×min versus RTEC: 
7,780±823.67) and the least squares means (Figure 3.5) at 120min (p=0.0058), 180min 
(p=0.006), and 240min (p=0.0047).  
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Figure 3.1 Visual analog scale ratings for hunger (n = 46) 
before and after consumption of oatmeal and a ready-to-
eat breakfast cereal (RTEC): Hunger was reduced to a 
greater extent with oatmeal as compared with the 
RTEC.*Least squares means: {120 minutes (p=0.0197), 
180 minutes (p=0.0003) and 240 minutes (p= 0.0036)}  
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Figure 3.2 Visual analog scale ratings for fullness (n = 
46) before and after consumption of the oatmeal and a 
ready-to-eat breakfast cereal (RTEC): Fullness increased 
to a greater extent with oatmeal as compared with the 
RTEC. *Least squares means: 120 minutes (p=0.0408), 
180 minutes (p=0.0061) and 240 minutes (p= 0.0102). 
 
Figure 3.3 Visual analog scale ratings for satisfaction (n = 
46) before and after consumption of the oatmeal and a 
ready-to-eat breakfast cereal (RTEC): Satisfaction was not 
significantly different between the breakfast meals.*Least 
squares means: p=0.0392 at 180 minutes.  
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Figure 3.4 Visual analog scale ratings for desire to eat (n = 
46) before and after consumption of the oatmeal and a 
ready-to-eat breakfast cereal (RTEC): Desire to eat was 
reduced to a greater extent with oatmeal as compared with 
the RTEC. *Least squares means: 120 minutes (p=0.0168, 
180 minutes (p<0.0001) and 240 minutes (p= 0.0022).  
Figure 3.5 Visual analog scale ratings for prospective 
intake (n = 46) before and after consumption of the oatmeal 
and a ready-to-eat breakfast cereal (RTEC): Prospective 
food intake was reduced to a greater extent with oatmeal as 
compared with the RTEC. *Least squares means: (120 
minutes (p=0.0058, 180 minutes (p=0.0006) and 240 
minutes (p= 0.0047). 
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Discussion 
The oatmeal breakfast resulted in a greater increase in perceptions of fullness, and a 
lower decrease in hunger, desire to eat, and prospective intake as compared with the RTEC. 
Satisfaction with the meal did not significantly differ between the two breakfast meals.  
In agreement with the hypothesis, oatmeal with a higher content of fiber increased satiety 
to a greater extent in the four hour period following consumption when compared with the 
RTEC. ß-glucan is the main component of oat soluble fiber and is primarily responsible for its 
physiologic effects.129 Humans lack the enzymes to hydrolyze ß-glucan which remains intact 
increasing the viscosity throughout the small intestine.129 The satiating effect of ß-glucan has 
been demonstrated in several studies however, the ß-glucan content ranged from 2.2 g to 9 g,85, 
88, 89, 120-122
 making it difficult to determine the concentration at which an increase in satiety is 
likely to occur. 
Using breakfast cereals containing oat ß-glucan and served with milk, Beck et al,88 
concluded that the optimal dose of β-glucan affecting satiety and other markers of appetite 
regulation were between 4g and 6g and that the hormonal effects were mediated through 
increased viscosity. However, the same investigators concluded in an earlier study that subjective 
satiety increased even at a relatively low dose of 2.2 g of oat β-glucan in a breakfast cereal that 
was served with milk.85 In other studies 1.2 g barley β-glucan in a meal replacement bar,19 had 
no effect on appetite ratings or food intake, but, a bread containing 3 g of a concentrated extract 
of barley β-glucan was demonstrated to control appetite in the short term (3 hours).89 However, 
breakfast cereals containing 4 g of oat ß-glucan did not result in a significantly prolonged period 
of satiety as compared with meals consisting of cornflakes123, 124 In the present study, it was 
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demonstrated that satiety increased to a greater extent with consumption of oatmeal containing 
2.3 g of β-glucan as compared with an oat-based RTEC. 
The physicochemical properties of β-glucan affect viscosity-dependent mechanisms. 
Viscosity is controlled by concentration in solution and molecular weight.131 β-glucan in foods 
not solubilized at 37ºC under physiologic conditions would not produce viscosity in the aqueous 
environment of the gut. Oat β-glucan is more soluble in hot water than in water at room 
temperature, so processing steps that involve moisture and heat will in all likelihood increase the 
solubility of β-glucan.132  The cooking of oats has been shown to increase the percentage of β-
glucan solubilized by three-fold.49 β-glucan is integral with cellulose and other noncellulosic 
polysaccharides in the cell wall and cooking releases it from this matrix.133 Thus, differences in 
the properties of β-glucan in each food may profoundly affect the physiologic response.  
The divergent results from various studies suggest that, although there may be a dose 
response relationship, the magnitude of the effect may also be controlled by the molecular 
weight and solubility of β-glucan under physiologic conditions. The increase in viscosity is 
considered to be the primary factor influencing the physiologic effects of β-glucan, but very few 
measurements of intestinal viscosity have been conducted, since such measurements are not 
readily obtained in people49, 157 It is therefore difficult to demonstrate a correlation of effect with 
viscosity.  Food structure and matrix under physiological conditions may have a role to play in 
appetite regulation.  
Breakfast cereals high in insoluble fiber have been demonstrated to increase satiety, 
however, the amounts tested ranged from 18-33 g/meal.87, 105, 106 In the present study the 
insoluble fiber content of the two breakfasts may have been too small (RTEC: 2.84 g and 
oatmeal: 3.34 g) to have an appreciable effect on satiety.  
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The protein content of the oatmeal breakfast was higher than the RTEC, and protein-
induced satiety has been demonstrated in several studies.27, 64, 65, 72 In a study comparing a high 
protein meal (25% of energy) with a low protein meal (10% of energy) it was found that satiety 
significantly increased after the high protein meal.64 A low fat chocolate milk drink (23% of 
energy from protein) increased satiety as compared with a cola drink (0% energy from protein).72 
In respiratory chamber experiments, energy expenditure and satiety have been shown to be 
greater with high protein diets (30% of energy) as compared with low protein diets (10% of 
energy).27, 65  These studies,27, 64, 65, 72 compared meals or diets that differed by 15% to 23% in 
their energy content from protein. 
 In contrast, a high protein breakfast (58.1% of energy from protein) did not significantly 
increase satiety three hours after consumption as compared with a high carbohydrate breakfast 
(19.3% of energy from protein) matched for weight, volume, fat and energy content, viscosity, 
and palatability (VAS ratings for taste and texture were not significantly different).69  In the 
present study, protein comprised 19.5% (RTEC) and 24.5% (oatmeal) of the energy contents of 
the meals, which is less than the proportion that has been shown to facilitate satiety. Thus, it is 
unlikely that the increase in satiety was mediated by protein. However, the higher protein content 
of the oatmeal breakfast cannot be completely ruled out as a mediating factor in the increase in 
satiety. 
There was no significant difference in the Gi of the two breakfast products tested, despite 
the lower sugar and higher fiber content of oatmeal (Predicted Gi based on Elquist method: 
oatmeal 84.5, RTEC 82.3). A lower glycemic response to food has been associated with a higher 
perception of satiety.18 The clinical relevance of the concept of Gi, however, remains unclear.  
The Gi is influenced by the nature of the starch, the physical form, the amount of fiber, fat and 
  
43 
 
protein, and the cooking times and methods.92 The random day-to-day variation in the glycemic 
response that occurs even in repeated experiments of the same food under standardized 
conditions is seemingly inexplicable.94 Thus, while protein may have contributed to satiety, the 
fiber content, especially β-glucan may have played the major role in enhancing satiety.  
This study had some limitations. The effects of oatmeal on appetite may have been 
mediated by hormone release, resulting from delayed intestinal transit of nutrients. Since 
hormone levels were not measured in this study it is difficult to draw any definitive conclusions 
as to the effects of hormones on appetite and satiety. The breakfasts were not matched for 
nutrient content, thus, it is difficult to clearly distinguish between the satiating effects of the 
nutrient components. Additionally, molecular weight and solubility of ß-glucan in the products 
used in the study were unavailable, precluding a comparison on that basis. Further, food intake at 
a subsequent meal was not assessed to determine a correlation between satiety and food intake. 
Conclusions 
In a comparison of two oat based cereals, oatmeal resulted in greater satiety than the 
RTEC over the four hour period following consumption. The increase in satiety sensations may 
be attributed to the satiating effects of the fiber and protein contents of oatmeal. The product 
delivering the nutrients may have a role to play in the bioavailability, functionality, and thereby 
the satiating effect of the various nutrient components.  
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CHAPTER 4 
EFFICACY OF OLIBRA: A 12 WEEK RANDOMIZED CONTROLLED 
TRIAL AND A REVIEW OF EARLIER STUDIES∗ 
 
Introduction 
The overweight and obese population both in the United States and globally, has 
increased over several decades. For example in the US, 68% of adults are overweight or obese.158 
The consequent rise in the associated diseases such as type 2 diabetes, cardiovascular diseases, 
and some cancers51, 58 is a major public health concern. It is estimated that health care costs 
attributable to overweight and obesity will double every decade, reaching 860.7 to 956.9 billion 
US dollars and accounting for 16-18% of total US health care costs by 2030.52 
Body weight is influenced by the interaction of biological, environmental, and 
physiologic factors. A number of hormonal, neuronal, and metabolic responses that orchestrate 
this process are located in the gut.57, 136, 137 Thus, the gastrointestinal (GI) tract plays a pivotal 
role in regulating food intake. The ileal brake is a negative feedback mechanism that is activated 
by the entry of nutrients into the ileum.135 The inhibitory effects of the activation of the ileal 
brake are a result of the interaction of neural and humoral signals31 exerting their influence on 
the proximal parts of the intestine. Exposure of the ileum to fats and fatty acids delays gastric 
emptying,36, 138prolongs GI transit time 37 and influences satiety.38, 39, 139  The physicochemical 
properties of fat affect its ability to regulate GI motor function, gut hormone release, and satiety. 
These effects are more pronounced with long chain fatty acids (≥12 carbons) than shorter chain 
fatty acids (≤10 carbons).40, 41 There is also growing evidence that free fatty acids are stronger 
                                                 
∗Originally appeared as Rebello CJ, Martin CK, Johnson WD, O'Neil CE, Greenway FL. Efficacy of Olibra: A 12-
Week Randomized Controlled Trial and a Review of Earlier Studies. J Diabetes Sci Technol 2012;6:95-708. 
Reprinted with permission from the Journal of Diabetes Science and Technology 
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mediators of the GI effects of fat than triacylglycerides.141 The role played by the degree of 
saturation in modulating the effects of fat on the GI tract has not been resolved fully.43, 44 
Delaying lipid digestion is an important factor in stimulating the ileal brake. By 
manipulating oil emulsions using galactolipids, lipolysis can be delayed through the inhibition of 
lipase activity.145   Olibra™ (Lipid Technologies Provider AB (Karlshamn, Sweden) is a fat 
emulsion comprised of fractionated palm, and oat oil in the proportion of 95:5. The palm oil is 
emulsified by hydrophilic galactolipids derived from oat oil.146  Olibra™ has been demonstrated 
in some studies to increase satiety and reduce food intake.23-25  Other studies, however, have not 
replicated these effects on food intake45, 46 although a positive effect on maintenance of weight 
loss149 and fat loss149, 150 have been demonstrated. Randomized, clinical weight loss trials have 
not been reported. Studies that employed methods of delivering the emulsion directly into the GI 
tract demonstrated a delay in GI transit.146, 159 However, when ingested orally, this fat emulsion 
may not elicit the GI responses manifested by an intragastric or intraduodenal administration.  In 
the dynamic environment of the GI tract, resistance of the emulsion to digestion is crucial for 
stimulating an increase in satiety and a reduction in food intake. 
The purpose of this study was to determine whether Olibra™ in conjunction with a 
healthy diet and exercise plan, would result in weight loss that was associated with a reduction in 
food intake.  The incidence of adverse effects of Olibra™ administration was also evaluated.  
Methods 
Subjects 
Subjects of both sexes 18-60 years of age, with a body mass index (BMI) between 25 and 
40kg/m2, inclusive, were recruited from the communities surrounding the Pennington 
Biomedical Research Center (PBRC) in Baton Rouge, Louisiana. Subjects were eligible for the 
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trial if they were determined to be healthy at a physical exam and had clinically normal findings 
in laboratory measurements. Questionnaires related to dietary restraint,61 sandwich rating to 
ensure that food used in the study was not disliked, and food selection,160 were completed. All 
subjects completed a 6-n-propylthiouracil161 test to determine if they were non-tasters, medium-
tasters, or super-tasters. Exclusion criteria included: (1) a dietary restraint score of > 13, (2) 
weight loss ≥ 4.5kg in the preceding three months, (3) a medical condition or taking regular 
medication (4) history of alcohol or other drug abuse in the preceding one year, and (5) 
pregnancy, lactation, or post-partum less than six months.  
The study was approved by the Institutional Review Board of the PBRC and participants 
provided written informed consent. The trial was registered on ClinicalTrials.gov under 
NCT01416051. 
Study Design  
The study followed a two-phased, randomized, placebo-controlled, double-blind, parallel 
design.  
Phase I  
At Visit 1 (Day -7±2) qualified subjects arrived at the PBRC in the morning after a 12-
hour overnight fast. Vital signs and weight were measured. Subjects were asked to consume an 
entire 382 kilocalorie (kcal) breakfast consisting of a serving of yogurt containing placebo (milk 
fat), followed by a cereal bar.  Subjects returned four hours later for a lunch meal consisting of a 
serving of yogurt containing placebo, followed by more sandwiches, chips, and cookies than 
could reasonably be consumed. They returned five hours later for a buffet dinner meal.  The food 
intake at lunch and dinner was determined by subtracting the weight of the uneaten food from its 
original weight.  The kcal and macronutrient intakes were calculated using product information, 
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and the USDA nutrient database.162 Subjective ratings (appetite and satiety) were recorded 
through visual analog scales (VAS). Concomitant medications and any adverse events were 
assessed throughout the entire study to determine the feasibility of subjects’ continuance with the 
study. One week later, at Visit 2 (Day 0±2), the subjects arrived at the PBRC in the morning 
after a 12-hour overnight fast and were randomized to the Olibra or placebo group.  Vital signs, 
weight, waist and hip circumferences, and body fat measurements were taken. The food intake 
test conducted at Visit 1 was repeated, except that subjects were given the yogurt with Olibra™ 
or the placebo added to it, at breakfast and lunch.   
Phase II 
After the food intake test at visit 2, subjects were instructed by a registered dietitian to 
follow a 1500-kcal diet, and encouraged to increase their current activity level.  Olibra™ or the 
placebo was dispensed in a double blind manner in ready to use portion packs. The subjects were 
instructed to consume the product twice daily, preferably with breakfast and lunch, for 12 weeks.    
Vital signs and weight measurements followed at Visits 3-6 (Days 14, 28, 56, 84, [±2]). Subjects 
were considered compliant if they consumed the recommended dose at least 70% of the time. At 
Visit 4, subjects repeated the food intake testing protocol followed at Visit 2. At Visit 6 (Day 
84±2), subjects arrived at the PBRC after a 12-hour overnight fast. Body fat, and waist and hip 
circumferences were measured. Blood tests, and the physical exam performed at screening were 
repeated at visit 6. A schedule of assessments is presented in Table 4.1. 
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Test Products 
One serving of the test product was 7.5 g (19kcal) providing 2.1 g of the fat emulsion, 
Olibra™. One serving of the placebo was also approximately 7.5 g (18.5 kcals), providing 1.95 g 
of 100% milk fat, and small amounts of carbohydrate (0.2 g) and protein (0.3 g). At the food 
intake tests, Olibra or the placebo was added to a 200 g carton of fruit flavored yogurt-194 kcals, 
1.8 g fat, 38.6 g carbohydrate and 5.8 g protein. 
 
 
Table 4.1 Schedule of study procedures, from screening visit to the end of study 
 PHASE I PHASE II 
Procedure Screening 
Visit 
 
Visit 1 
Baseline 
Day -7+2 
Visit 2 
Day 
0+2 
Visit 3 
Day 
14+2 
Visit 4 
Day 
28+2 
Visit 5 
Day 
56+2 
Visit 6 
Day 
84+2 
Medical History  X       
Physical Exam X      X 
Height X       
Weight X X X X X X X 
Vital Signs (BP, Pulse rate) X X X X X X X 
Body Composition X  X    X 
Waist and Hip Circumference X  X    X 
Chemistry panel X      X 
Lipid profile X      X 
Complete blood count, with 
differential 
X      X 
Concomitant Medications X X X X X X X 
β-HCG Pregnancy Test-Urine X       
PROP taste-sensitivity test X       
Visual Analogue Scales   X X  X   
Eating Inventory X    X   
Food Selection Questionnaire X       
Sandwich Rating 
Questionnaire 
X       
 
Cold/Allergy Questionnaire  X X  X   
Dietitian consultation   X     
Adverse Events  X X X X X X 
Food Intake Tests (w/placebo)  X      
Food Intake Tests (w/test 
product or placebo) 
  X  X   
  
49 
 
Measurements 
Anthropometry 
Body weight was measured163 at all visits. Fasting measurements were taken, at 
screening, and at visits 1, 2, 4 and 6. Height was measured163 at screening to determine BMI 
(weight [kg]/height squared [m2]). Waist and hip circumferences were measured163 and the 
waist/hip ratio was calculated.164 Body composition was measured using bioelectrical impedance 
(RJL Systems, BIA101A, Clinton Township, Michigan). 
Questionnaires 
Each food intake test was preceded by a questionnaire about colds or allergies that might 
affect taste.  Eating Inventory (EI)31 was administered at screening, and  prior to the food intake 
test on day 28. The food intake tests were accompanied by visual analog scales administered 
before and after, breakfast, lunch, and dinner. Participants rated their degree of each subjective 
state by placing a hash mark on a 100 mm line.  The 100 mm line was anchored using the 
descriptors “Not at all” to “Extremely”.  Hunger, fullness, desire to eat, food craving, desire for 
sweet, desire for salty, and desire for fatty foods were assessed. Visual analog scales were also 
used to assess hedonic (sensory) responses to the yogurt served at breakfast and lunch, on all 
food intake test days.  The Food Selection Questionnaire32 was used to rate the participants’ food 
preferences, from a wide variety of foods that were offered at the buffet dinner meals.  
Adverse Events 
An adverse event was defined as any adverse change from baseline (pre-treatment) 
condition, which occurred during the course of the study after treatment had started, whether 
considered related to treatment or not. All adverse events, including intercurrent illnesses and an 
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increase in severity or frequency of a concomitant sign/symptom of a concomitant illness, were 
documented.  
Statistical Analysis 
The food intake testing reported in the literature suggests that Olibra™ will reduce food 
intake by 20-30%.23-25   From past experience, one can detect a 12% decrease in food intake in 
the eating laboratory with 30 subjects as their own controls.165 The difference in food intake 
decreases with time on a diet.165  Therefore, 82 subjects were randomized in this study.  This 
allowed for 30 subjects per group to complete week 4 of the study assuming a 30% 
dropout.  Assuming a standard deviation of 2.3 kg and an alpha of 0.05 the study was powered at 
89% to detect a difference of 2 kg in weight loss between the groups at 12 weeks, if 28 subjects 
finish per group.   
Observations made during Visit 1 of the study were considered as baseline 
measurements.  A repeated measures analysis of covariance (ANCOVA), with baseline 
covariates, was used to test if change in energy intake from baseline to week four differed 
significantly between the test and control groups.  Body weight, percent body fat, waist 
circumference, waist/hip ratio, and EI scores were analyzed similarly.  The changes from 
baseline, for the scores for appetite and satiety assessed through VAS, were analyzed by doubly 
repeated measures ANCOVA. Visual analog scales used to assess hedonic responses to the test 
and control yogurt were analyzed directly, rather than as change scores in a repeated measures 
analysis of variance. Chi-square test was used to analyze the distribution of tasters. Food intake 
and body weight were analyzed by stratifying taster status. Post hoc tests when conducted 
followed the Tukey-Kramer adjustment. All analyses were carried out using SAS (v. 9.2; SAS 
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Institute, Inc., Cary, NC). Subject characteristics are presented as mean ± SD and efficacy 
endpoints are presented as mean ± standard error of the mean (SEM). 
Results 
Data related to 71 subjects were analyzed, and 57 subjects completed the study (Figure 
4.1). Descriptive characteristics of the subjects at baseline are summarized in Table 4.2.  
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5 withdrew  
1 started medication 
n = 34 
134 subjects screened 
82 enrolled 
41 randomized to test 
group 
41 randomized to control 
group 
2 withdrew 
1 missed visit 
n = 31 
1 withdrew 
n = 31 
0 withdrew 
n = 34 
3 withdrew 
n = 28 
1 withdrew 
n = 34 
3 withdrew 
n = 25 
2 withdrew 
n = 32 
3 withdrew  
1 started medication 
n = 37 
2 withdrew 
1 missed visit 
n = 34 
1 withdrew 
n = 40 
0 withdrew 
n = 41 
Figure 4.1 Subject recruitment, randomization, and continuance with 
the study 
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Table 4.2 Subject characteristics at baseline, including 
demographics  
  
  Total (n = 71) Test (n = 34) Control (n = 37)  
  Mean ± SD Mean ± SD Mean ± SD P value 
Age (years) 40.5 ± 12.1 38.4 ± 12.8 42.4 ± 11.2 0.2 
Height (cm) 166.4 ± 8.41 166.0 ± 8.2 166.7 ± 8.7 0.7 
Weight (kg) 89.3 ± 13.0 88.5 ± 14.6 90.0 ± 11.5 0.6 
BMI (kg/m2) 32.3  ± 3.92 32.1 ± 4.5 32.4 ± 3.4 0.7 
Waist (cm) 97.6 ± 9.3 98.1 ± 10.5 97.2 ± 8.3 0.7 
Hip (cm) 112.6 ± 7.9 111.9 ± 8.7 113.3 ± 7.1 0.5 
Body Fat % 40.7 ± 6.0 40.3 ± 6.9 41.1 ± 5.0 0.6 
Waist/Hip Ratio 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.7 
          
  
n (%) n (%) n (%) 
  
Sex     
Female 60 (84.5) 28 (82.3) 32 (86.5)  
Male 11 (15.5) 6 (17.7) 5 (13.5)  
Race     
White 47 (66.2) 22 (64.7) 25 (67.6)  
Black 24 (33.8) 12 (35.3) 12 (32.4)  
       
 
Anthropometry 
At the end of 12 weeks body weight was significantly reduced in both groups (test group: 
2.17±0.46 kg, P<0.0001) (control group: 1.68±0.42 kg, (P<0.0001) with no significant difference 
between groups (Table 4.3). The waist circumference decreased by 2.93±0.85 cm in the test 
group (P=0.001), and by 1.78±0.74 cm in the control group (P=0.02), with no significant 
difference between the two treatment regimens. The waist/hip ratio decrease by 0.014±0.007 in 
the test group and by 0.012±0.006 in the control group was not significant, with no statistical 
difference between the groups. Neither group experienced a significant change in per cent body 
fat or lean tissue as assessed by bioelectrical impedance. 
 
 
  
53 
 
Table 4.3 Body weight and body composition measurements, from Day -7  to Day 84, including change from Day 
0 to Day 84 (Between group P value = non-significant) 
  
Day -7 Day 0 Day 14 Day 28 Day 56 Day 84 ∆ Day 0 - Day 84 P-value 
Test  n = 34 n = 34 n = 31 n = 31 n = 28 n = 25 n = 25  
Control n = 37 n = 37 n = 34 n = 35 n = 34 n = 32 n = 32  
Weight (kg)         
Test  88.4 ± 2.2 88.5 ± 2.2 87.1 ± 2.2 87.1 ± 2.2 86.6 ± 2.2 86.4 ± 2.2 -2.17 ± 0.5 < 0.0001 
Control  90.0 ± 2.1 90.0 ± 2.1 90.0 ± 2.1 89.2 ± 2.1 88.9 ± 2.1 88.3 ± 2.1 -1.68 ± 0.4 < 0.0001 
% Change in Weight         
Test  . 0.2 ± 0.4 -1.4 ± 0.42 -1.4 ± 0.4 -1.9 ± 0.4 -2.1 ± 0.5 -2.2 ± 0.5 < 0.0001 
Control  . 0.1 ± 0.4 -1.0 ± 0.4 -0.8 ± 0.4 -1.2 ± 0.4 -1.8 ± 0.4 -1.9  ± 0.4 < 0.0001 
Waist (cm)         
Test  - 98 ± 1.6 - - - 95.0 ± 1.7 -2.9 ± 0.9 0.001 
Control - 97.2 ± 1.5 - - - 95.5 ± 1.6 -1.8 ± 0.7 0.02 
Waist/hip Ratio   - - -    
Test - 0.87 ± 0.01 - - - 0.86 ± 0.01 -0.01 ± 0 0.06 
Control - 0.86 ± 0.01 - - - 0.85 ± 0.01 -0.01 ± 0 0.08 
% Body Fat   - - -    
Test - 39.7 ± 1.0 - - - 38.8 ± 1.1 -0.9 ± 0.6 0.13 
Control - 40.8 ± 1.0 - - - 40.2 ± 1.0 -0.6 ± 0.6 0.31 
          
Values are mean ± SEM 
-Waist, waist/hip ratio, and % body fat were measured on days 0 and 84 
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Food and Energy Intake 
There were no significant differences in the mean energy, macronutrient or amount of 
food consumed in the test group when compared with the control group (Table 4.4). Based on 
within group analyses, on Day 0, there was no significant change in the energy, macronutrient, or 
amount of food consumed in the test group, as compared with their intake, on Day -7. The results 
were similar for the lunch, dinner, and the total (lunch + dinner) meal intake.  
Subjective Ratings 
No significant treatment effects were found for any of the appetite and satiety measures over the 
various time periods. There was no significant difference in VAS ratings of pleasantness, 
palatability, desirability, and capacity to satiate between the test and control yogurt served at the 
food intake tests. 
Adverse Events 
Fifty-eight adverse events were reported (test group: 26, control group: 32). Forty adverse events 
were resolved (test group: 20, control group: 20). There were 18 adverse events ongoing at the 
end of the study.  Six were reported in the test group and 12 in the control group (Table 4.5). 
There were no serious adverse events (life threatening, requiring hospitalization, or significantly 
disabling). 
6-n-propylthiouracil Test 
There were 24.2% supertasters, 57.6% medium tasters, and 18.2% non-tasters in the test 
group as compared with 21.6% supertasters, 62.2% medium tasters, and 16.2% non-tasters in the 
control group. Taster status did not indicate a differential response to food intake, or an influence 
on body weight. 
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Table 4.4 Energy, macronutrient, and food intake determined at lunch and dinner, including the combined (lunch + 
dinner) intake, pre- and post- intervention (Between group P value = non-significant) 
  
Day -7  Day 0  Day 28a 
  Test Control  Test Control  Test Control 
Lunch n = 34 n = 37  n = 34 n = 37  n = 30 n = 35 
Energy Intake (kcal) 654.2 ± 47.8 588.9 ± 45.8  639.5 ± 47.8 606.7 ± 45.8  639.2 ± 49.2 601.1 ± 46.4 
Food Intake (g) 700.4 ± 36.3 663.5 ± 34.8  661.4 ± 36.3 613.2 ± 34.8  637.2 ± 37.9 549.2 ± 35.5 
Fat (g) 27.9 ± 2.7 23.4 ± 2.2  26.2 ± 2.7 23.7 ± 2.2  27.5 ± 2.3 25.7 ± 2.2 
Cho (g) 70.8 ± 5.6 65.7 ± 5.4  71.5 ± 5.6 69.1 ± 5.4  69.5 ± 5.8 66. 8 ± 5.4 
Protein (g) 28.4 ± 2.0 27.3 ± 1.9  27.9 ± 2.0 27.6 ± 1.9  27.0 ± 2.0 24.5 ± 1.9 
         
Dinner n = 34 n = 35c  n = 34 n = 35c  n = 29b n = 32c 
Energy Intake (kcal) 948.9 ± 58.3 915.3 ± 57.4  838.0 ± 58.3 788.9 ± 57.4  720.2 ± 60.9 662.8 ± 58.9 
Food Intake (g) 419.7 ± 30.0 418.9 ± 29.6  383.3 ± 30.0 380.4 ± 29.6  342.0 ± 31.2 326.8 ± 30.2 
Fat (g) 44.7 ± 3.3 46.6 ± 3.3  39.0 ± 3.3 39.5 ± 3.3  32.5 ± 3.5 32.2 ± 3.4 
Cho (g) 102.4 ± 6.4 88.0 ± 6.3  91.3 ± 6.4 77.1 ± 6.3  80.5 ± 6.7 69.0 ± 6.5 
Protein (g) 36.9 ± 2.7 36.5 ± 2.7  32.4 ± 2.7 31.9 ± 2.7  27.2 ± 2.8 25.0 ± 2.7 
         
Lunch + Dinner n = 34 n = 35  n = 34 n = 35  n = 29 n = 32 
Energy Intake (kcal) 1603 ± 91.2 1484.1 ± 89.8  1477.5 ± 91.2 1376.1 ± 89.8  1350.7 ± 94.8 1239.7 ± 91.1 
Food Intake (g) 1120.1 ± 56.0 1074.8 ± 55.2  1044.7 ± 56.0 992.8 ± 55.2  988.6 ± 58.2 867.1 ± 56.4 
Fat (g) 72.6 ± 4.8 69.4 ± 4.8  65.2 ± 4.8 62.5 ± 4.8  59.9 ± 5.0 57.0 ± 4.9 
Cho (g) 173.2 ± 9.9 150.7 ± 9.8  162.9 ± 9.9 143.3 ± 9.8  148.7 ± 10.6 132.6 ± 10.0 
Protein (g) 65.3 ± 3.9 63.3 ± 3.9  60.3 ± 3.9 59.1 ± 3.9  53.8 ± 4.1 48.7 ± 4.0 
          
Values are mean ± SEM 
a
 1 subject (control group) missed visit  
b
 1 subject missed dinner,  
c
 Outliers in the data (all dinner records of 2 subjects and 1 dinner record of 1 subject, that could not be verified)    removed from analysis 
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Table 4.5 Adverse events reported during the study period, including those resolved and those 
ongoing at the end of the study 
Effect Resolved Ongoing at End of Study Test Group Control Group Test Group Control Group 
Neurological     
 Headache 6 4  2 
 Insomnia 1    
Musculoskeletal     
 Muscle Pain 1    
 Back Pain 2 2  1 
Gastrointestinal     
 Diarrhea 1 1  1 
 Abdominal Pain 1 1   
 Nausea / Vomiting 1 1   
 Heartburn/Indigestion  1  2 
Oral Complaints 2  1  
Dermatologic     
 Foot Infection 1    
 Rash   1  
 Pruritus    1 
Respiratory     
 Cough /Cold  1 2  1 
 Sinus Infection  1 1 1 
 Allergy  2  1 
 Other  1   
Cardiovascular     
 Hypertension    1 
 Chest Pain    1 
 Dizziness  1   
Genitourinary     
 Menstrual Cramps   1   
 Urinary Tract Infection  1   
Non-specific     
 Viral Infection 1    
 Fatigue  1   
 Anxiety   1  
 Special Senses/Other 2  2  
Total: 20 20 6 12 
Four adverse events in the control group (2 indigestion, 1 diarrhea, and 1 dizziness were reported as possibly 
related to the treatment. No treatment related adverse events were reported in the test group 
 
Eating Inventory 
There were no significant changes in the scores for dietary restraint and disinhibition, 
however, hunger scores were significantly reduced in the test group as compared with the control 
group  (P=0.0082) (Figure 4.2). 
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Discussion 
At the end of 12 weeks, a reduction in body weight and waist circumference did occur 
but the differential reduction was not statistically significant between the groups. EI scores for 
hunger, which reflect an individual’s perception of hunger feelings, were significantly reduced in 
the test group as compared with the control group, however, no significant treatment effects were 
observed on energy intake, food intake, and appetite and satiety ratings after four weeks of 
Olibra consumption.  
Earlier studies23-25 all crossover designs, reported a reduction in energy, macronutrient 
and total weight of food intake, following consumption of the Olibra™ emulsion. The 
suppressive effects on appetite ratings (hunger, desire to eat, and preoccupation with thoughts of 
food or perceived fullness) in the short term were only demonstrated in one study24 and one part 
of another.23 In the present study, there was no significant reduction in energy, macronutrient or 
total weight of food intake four hours or nine hours after consumption of Olibra™, based on 
within and between group analyses.  Crossover designs minimize the errors of individual 
variability, hence the present study was designed to evaluate the acute effects of Olibra™ using a 
Figure 4.2 Hunger scores on Eating Inventory (EI) collected 
at screening and prior to food intake test, on Day 28(P = 
0.0082). Values are mean ± standard error of the mean.  
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within subjects analysis, in addition to its effects on two different groups. Using self-reported 
food intake data, Burns et al25 concluded that the treatment effects of Olibra™ were maintained 
up to 36 hours. However, self-reported data are notorious for their susceptibility to misreporting 
and altered feeding behavior. 
Two subsequent studies failed to confirm the reduction in energy intake,45, 46 though a 
suppressive effect on appetite ratings (hunger, fullness, desire to eat, and prospective intake or 
preoccupation with thoughts of food) was demonstrated.46 No effect on body weight, body 
composition or waist circumference was observed after three weeks consumption of Olibra™.45 
A meta-analysis147 of the short term effects of Olibra™ on food intake attributed the differences 
in findings partly to the manufacture, processing, or preparation of Olibra™. It has been 
speculated that the functional integrity of the Olibra™ emulsion structure is affected when it is 
subjected to processing such as homogenization and pasteurization, along with the yogurt. The 
emulsion used in the present study was added after the yogurt, served at the food intake tests, 
was manufactured.  It was therefore not subjected to further processing. The demonstrated 
efficacy of unprocessed as compared with processed Olibra™, in reducing energy and food 
intake148 at eight hours was not observed. However, these investigators also found no effects on 
hunger, fullness and satiety. 
All of the studies that investigated the effects of oral ingestion of Olibra™ used between 
four and five grams of the emulsion, except for one study25 that investigated the dose response 
using 2, 4, and 6 g, and found no difference between the doses.  Eating behavior comprises a 
large learned and anticipatory component.127  Behavioral and environmental factors can 
overcome physiological drives and influence feeding behavior.153 Therefore, a physiological 
impetus would have to be sufficiently large to consistently correlate with altered energy and 
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nutrient intakes. Additionally, the relatively small sample sizes used in all the studies resulted in 
divergent results since the actual difference was much smaller than the expected difference.   
The beneficial effects of Olibra™ on body composition and weight maintenance after 
weight loss have been demonstrated,149 however, Olsson et al150 observed no effect on weight, 
but body fat mass decreased, after an initial weight loss period. In these studies, the calorie 
restriction imposed during the weight loss period may have had a role to play in the 
demonstrated effects. In humans, it has been shown that exposure to a high fat or high energy 
diet decreases sensitivity to the GI mechanisms involved in appetite regulation.22, 141, 151 High fat 
diets have been shown to modify appetite perceptions, increasing hunger and decreasing 
fullness.152 If the subjects in the present study usually consumed a high fat or high calorie diet 
the effect of Olibra™ could have been attenuated. Nevertheless, the ultimate goal of altering 
appetite and satiety signals is to correct energy imbalance and reduce weight, which as 
demonstrated in this study, was far from accomplished with the consumption of Olibra™.  
A 45 minute delay in intestinal transit time following consumption of Fabuless™ (also 
known as Olibra™) has been reported30 but, the computation of orocecal transit time has been 
questioned.41 Using an intragastric administration technique to infuse Fabuless, Knutson et al22 
concluded that the palmitic acid crystals observed in the jejunal samples of subjects caused a 
reduction in intestinal digestion and absorption rates. Both studies used a single dose of 8.5 g of 
Olibra™ to produce these effects which is about twice the daily dose used in the present study.  
While it is important to demonstrate that Olibra™ produces conditions conducive to stimulation 
of the ileal brake mechanism, such manipulation must also produce the directional changes in 
feeding behavior consistent with the activation of this mechanism.  
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The present study is limited by the non-availability of information related to subjects’ 
usual intake, to determine if previous patterns of nutrient exposure were related to the results of 
the study. A review of published human studies that investigated the effects of Olibra™ is 
presented in Table 4.6.  
Conclusion 
The Olibra™ emulsion had no significant effect on food intake, appetite and satiety 
ratings, body weight, or body composition. The results of studies indicating the beneficial effects 
of Olibra have not been confirmed in separate studies. A review of the available evidence 
indicates that further investigation of Olibra™ as a means of regulating appetite, satiety, food 
intake, and thereby body weight is not warranted.
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Table 4.6 Review of Published Studies that Investigated the Effects of Olibra 
Source Study Overview Summary of Results Conclusions 
Burns et al, 200023 Aim: To investigate the short term effects of  Olibra on   
   energy and macronutrient intake in non-obese subjects 
Subjects: 59 total participants  
Study 1:15 females, 14 males                  
Study 2: 16 females,14 males 
Age: 18-65 years 
BMI: ≤ 30 
Study Design: Two RDBPCa WSb  crossover studies three 
months apart. 
Intervention: An emulsion in yogurt to provide 5 g of fat 
as Olibra (1 treatment) 
Length of Each Study: 2 visits with a one week interval 
between crossover 
Food intake test: 4 h after consumption of  test or placebo 
 product. Free living weighed intake recorded in food 
diaries for rest of day 
Subjective Ratings: VASc before and after eating yogurt 
 and at hourly intervals until 2100h on test days 
 
Food Intake: Lower mean energy, 
macronutrient, and total weight of 
food, intake after consuming test 
product 
Energy Intake: 
P < 0.001 (Study 1) 
P < 0.001 (Study 2) 
P < 0.001 (Combined studies) 
 
Subjective Ratings: Reduced  
hunger, desire to eat and 
preoccupation with food in Study 1 
but not in Study 2 or combined 
studies 
Study 1: 
P = 0.002 (Hunger) 
P = 0.006 (Desire to eat) 
P < 0.001 (Preoccupation with food) 
Conclusions: The  
physicochemical 
characteristics of small 
amounts of dietary fat 
affect short term satiety 
Burns et al, 200124 Aim: To investigate the effects of Olibra on energy and  
macronutrient intakes up to 8 h in non-overweight, 
overweight, and obese subjects. 
Subjects: 60 total participants 
Non-overweight: 20 (10 females, 10 males)        
Overweight: 20 (10 females, 10 males)                          
Obese:20 (13 females, 7 males) 
Age: 18-65 years 
BMI: 20 - 30+ 
Study Design: RDBPC, WS, crossover 
Intervention: An emulsion in yogurt to provide 5g of fat  
as Olibra (1 treatment) 
Length of Study: 2 visits with a one  week interval  
between crossover 
Food intake test: 4h and 8h after consumption of test or  
 placebo product. Free living weighed intake recorded in 
food diaries for rest of day, and following day to 2100 h 
Subjective Ratings: VAS before and after eating yogurt 
 and at hourly intervals until 2100h on test days 
Food Intake: Lower mean energy  
and macronutrient intake in non-
overweight, and overweight after 
consuming test product at 4h, and in 
all groups after consuming test 
product, at 8h. No overcompensation 
in next 24h 
Energy Intake, 4h/8h: 
P < 0.01/p < 0.001 (non-overweight) 
P < 0.001/p < 0.001 (overweight) 
P > 0.05/p < 0.01 (obese) 
P < 0.001 (total group at 24h) 
 
Subjective Ratings: Reduced  
hunger, desire to eat, and 
preoccupation with food, and greater 
perceived fullness 
P < 0.05  
Conclusions: Effects of  
Olibra were maintained 
at least until 8h and 
were evident in non-
overweight, overweight 
and obese subjects 
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Table 4.6 (continued) 
Source Study Overview Summary of Results Conclusions 
Burns et al, 200225 Aim: To investigate if the energy and macronutrient 
intake responses to Olibra are dose-dependent, and are 
maintained up to 36h  
Subjects: 50 total participants 
30 females, 20 males 
Age: 18 - 65 years 
BMI: 20 – 25 kg/m2 
Study Design: RSBPCd, WS, crossover 
Intervention: 5, 10, 15g emulsions in yogurt to provide  
2, 4, and 6g of fat respectively as Olibra (3 treatments) 
Length of Study: 4 visits with a one week interval 
 between visits 
Food intake test: 4h after consumption of test or placebo  
product. Free living weighed intake recorded in food 
diaries for rest of day and following day to 2100 h 
Subjective Ratings: VAS before and after eating yogurt 
 and at hourly intervals until 2100h on test days 
 
Food intake: Lower mean energy  
(21, 25, and 30% with 2,4, and 6 g of 
Olibra fat emulsion, respectively) 
macronutrient, and total weight of 
food, intake after consuming test 
product. Lower energy and 
macronutrient intakes up to 36h  
Energy Intake: 
P < 0.001 (at each dose) 
P < 0.001 (at each dose at 36h) 
 
Subjective Ratings: No effect 
between doses, and with control 
Conclusions: Effects of 
Olibra were dose 
dependent but results 
were not consistent 
across gender or 
proportional across 
dose levels. Effects 
were maintained at 36h 
Logan et al, 200626 Aim: To investigate the medium term effects of Olibra 
on appetite and food intake in non-obese subjects. 
Subjects: 28 total participants 
14 females, 14 males 
Age: 20 – 55 years 
BMI: < 30 kg/m2 
Study Design: RDBPC, WS, crossover 
Intervention: A 12.5g emulsion in yogurt drink to 
provide 5g of fat as Olibra (22 treatments) 
Length of Study: 2 x 3 weeks study phases separated by 
a 3 week wash out phase.  
Food intake test: 4 h after consumption of  test or  
placebo product on days 1, 8, and 22. Free living 
weighed intake recorded in food diaries for rest of day 
and following day 
Anthropometry: Body weight and body composition 
measured on days 1, 8, and 22. 
Subjective Ratings: VAS before and after eating yogurt 
 and at hourly intervals until 2100h on  test days 
 
Food Intake: No treatment effect on  
energy, macronutrient, and total 
weight of food, intake 4h after 
consuming test product. No treatment 
effect on intake during remainder of 
day and post-test day 
 
Anthropometric Indices: No treatment   
effect on body weight, body 
composition or waist circumference 
 
Subjective Ratings: No treatment effect 
 
Blood Parameters: No effect on  
lipid levels but reduction in fasting 
blood glucose during test treatment 
P = 0.018  
Conclusions: There was  
no evidence of short or 
medium term effect of 
Olibra on food intake 
or appetite 
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Table 4.6 (continued) 
Source  Study Overview Summary of Results Conclusions 
Diepvens et al, 200728 Aim: To investigate the effects of Olibra on weight  
maintenance after a very low calorie diet. 
Subjects: 50 female participants 
Age: 18 – 58 years 
BMI: 25 – 32 kg/m2 
Study Design: RDBPC, parallel 
Intervention: 5g emulsion in yogurt to provide 2g fat 
as Olibra (twice daily = 252 treatments) 
Length of Study: 26 weeks – 6 weeks weight loss  
period with a very low energy diet, followed by 18 
week weight maintenance period with test product 
or placebo 
Anthropometric Measurements: Weeks 2, 8, and  26 
Satiety tests: Test or placebo product consumption  in  
the morning. VAS recorded hourly until 1300h, in 
weeks 1, 7 and 25 
Blood Tests: Fasting, and 90 and 180 minutes after 
test or placebo product consumption at satiety tests 
REE Measurement: Weeks 2, 8, and 26 
 
As Compared with Placebo Group: 
Weight: There was no significant  
increase in body weight in test group 
P < 0.001 
Body Composition: Decrease in fat 
mass and increase in fat free mass 
 in test group.  p < 0.05 
BMI/Waist circumference: No increase 
in test group. p < 0.05 
REEe:: Measured REE as a function  
of fat free mass was higher than 
predicted REE in test group 
 P < 0.05 
Blood Parameters: Increase in  
GLP-1 values 180 min after test 
product consumption. p < 0.05 
Subjective Ratings: Decrease in 
hunger 4 h after test product 
consumption.  p < 0.05 
Conclusions: Long term  
consumption of Olibra 
had beneficial effects 
on weight maintenance 
and body composition 
after initial weight loss 
Diepvens et al, 200827 Aim: To investigate the short term effects of  Olibra 
on satiety and energy intake 
Subjects: 41 female participants 
21 junior normal weight 
20 senior overweight 
Age: 18 – 50 years 
BMI: 20 – 30 kg/m2 
Study Design: RDBPC, WS crossover 
Intervention: 10g emulsion in yogurt to provide  4g 
fat as Olibra (1 treatment) 
Length of Study: 2 visits with a one week interval 
between crossover 
Food intake test: 4 h after consumption of test or  
placebo product 
Subjective Ratings: VAS at hourly intervals 4 times 
after consumption of test or placebo product 
 
Food intake: No treatment effect 
 
Subjective Ratings: Suppressive 
effect over appetite ratings at 3 h, and 
lower return to baseline hunger in 
normal weight women aged between 
18 and 30 years 
P < 0.05 (hunger) 
P < 0.05 (desire to eat) 
P < 0.05 (return to baseline hunger) 
  
 
Conclusions: Olibra 
exerted a suppressive 
effect on appetite 
ratings in the short term 
and may prevent 
overeating 
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Table 4.6 (continued) 
Source Study Overview Summary of Results Conclusions 
Haenni et al 200930 Aim: To investigate the effects of Fabulessf on  
orocecal transit time 
Subjects: 15 male participants 
Age: 20 – 59 years 
BMI: 22 – 28 kg/m2 
Study Design: RDBCgcrossover 
Intervention: An emulsion in yogurt to provide 8.5g  
of fat as Fabuless (1 treatment). . 
Length of Study: 2 visits with a one week interval  
between crossover 
Food Intake: Nutritional drink with 1000mg  
salazopyrine 3h after consumption of test or control 
product, followed by lunch 4h later. Dinner was 
served 4h after lunch  
Blood Tests: Before lunch and every hour until 11h  
after lunch 
 
Blood parameters: A delay in the  
appearance of serum sulfapyridine (a 
metabolite of salazopyrine), in the 
test group compared with the control 
group, corresponded to a 45 minute 
delay in orocecal transit time. 
P < 0.05 
Conclusions: Fabuless   
may stimulate the ileal 
brake mechanism by 
increasing GI transit 
time 
 
Knutson et al 201022 Aim: To investigate the differences in digestion and  
absorption of Fabuless compared with milk fat 
Subjects: 16 total participants 
12 females, 4 males 
Age: 23 – 36 years 
BMI: 19 – 29 kg/m2 
Study Design: RDBPC, crossover 
Intervention: An emulsion in yogurt to provide 8.5g  
of fat as Fabuless (1 treatment) 
Length of study: 3 months – 2 visits with  ≥  5 day  
interval between crossover  
Route of administration: Intragastric perfusion of  
test or control yogurt. 
Intestinal Samples: Collected every 30 minutes  
following intragastric perfusion of test or control 
yogurt 
 
Jejunal sample: Test group had higher 
lipids mainly as free fatty acids, than 
control group. Needle shaped 
palmitic acid crystals were observed 
only in test group 
P < 0.05 (total lipids) 
P < 0.05 (free fatty acids) 
 
Conclusions:  Higher  
amount of lipids in the 
proximal jejunum, and 
crystallization of lipids, 
after infusion of 
Fabuless, makes it 
possible for sufficient 
lipids to reach the 
ileum and activate the 
ileal brake.  
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Table 4.6 (continued) 
Source Study Overview Summary of Results Conclusions 
Olsson et al 201129 Aim: To investigate the effects of Fabuless on body 
weight and body composition after initial weight 
loss 
Subjects: 43 females 
Age; 18 – 60 years 
BMI: 26 - 31 kg/m2 
Study Design: : RDBC, parallel 
Intervention: A 12.5g emulsion in ready to use portion  
packs, added to meal replacement drink, to provide 
5.2 g of fat as Fabuless (84 treatments) 
Length of Study: 18 weeks – 6 week weight loss  
period with calorie restricted diet, followed by 12 
week weight maintenance period with test or control 
product 
Anthropometric measurements: Baseline and weeks 4, 
8, and 12. 
 
Weight: Significant reduction in both 
groups but no difference between 
groups 
 
Body Fat Mass: Decrease in body  
fat mass in test group as compared 
with control group 
P < 0.05 
 
Waist circumference: Significant  
reduction in test group but no 
differences between groups 
 
Muscle mass and hip circumference: 
No treatment effects 
 
Conclusions: The  
addition of Fabuless to 
a meal replacement diet 
plan resulted in a 0.9% 
decrease in body fat 
mass with no change in 
body weight between 
the groups. 
Smit et al 201139   Aim: To investigate the effects of Fabuless on appetite 
and food intake and to establish the impact of 
processing on its efficacy 
Subjects: 24 total participants 
16 female, 8 male 
Age: 18 – 43 years 
BMI: 18 – 37 kg/m2 
Study Design: RDBPC, crossover 
Intervention: A 12.5g emulsion in yogurt-based  
 beverage to provide 5 g of fat as Fabuless (2 
treatments –1 processed,1 unprocessed) 
Length of Study: 4 weeks – 3 testing days over a 2  
week period 
Food intake test: 4h and 8h after consumption of  
test or placebo product 
Subjective Ratings: VAS at baseline and every 30  
 minutes post-treatment  until after dinner, on test 
days 
Food intake: Reduced food intake  
8h after treatment, only if active 
ingredient was added at the end of 
manufacture 
P < 0.01 
 
Subjective Ratings: No treatment effect  
on appetite and satiety 
Conclusions:  
Unprocessed Fabuless 
had a modest effect on 
food and energy intake. 
No effect when active 
ingredient was added to 
yogurt prior to 
homogenization and 
pasteurization 
aRandomized double blind placebo-controlled, bWithin subject,  cVisual analog scales dRandomized single blind placebo-controlled, eResting energy 
expenditure,  fAlso known as Olibra, gRandomized double blind controlled 
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CHAPTER 5 
SUMMARY 
 
The studies showed that oatmeal enhanced satiety, as compared with a RTEC in the four 
hour period following consumption, however the Olibra™ fat emulsion had no effect on satiety 
or food intake in the four or eight hour period following consumption. Additionally, regular 
consumption of Olibra™ had no effect on food intake after four weeks, or body weight and body 
composition at the end of 12 weeks. 
Appetite sensations arise out of a convergence of several factors related to biology and 
the environment. It seems unlikely that biological imperatives and environmental cues will in all 
instances lead to exactly the same outcome. Manipulation of nutritional components may elicit a 
behavioral response when certain physiologic, psychologic, or contextual conditions are present. 
Thus, it is futile to imagine that anything other than a multifaceted relationship exists between 
food intake (the expression of appetite) and appetite control. If consumption of a particular food 
results in an increase in satiety in the short term, the question arises as to whether it causes a 
reduction in energy intake at a subsequent meal and a sufficient restraint is demonstrated over 
energy compensation mechanisms during the course of the day. The crux of the issue however, is 
whether repeated consumption of a particular food, has enduring effects on energy intake that 
translate into a loss of body weight. 
Hunger, fullness, desire to eat, and prospective intake are indices of the drive to eat, and 
these sensations can be reliably measured through subjective or behavioral tests of satiety.4 The 
desired directional changes in these indices are quite plainly not the same as a reduction in food 
intake. Nevertheless, they have immense value if consumption of healthier foods, recommended 
alterations in nutrient profile, or adherence to calorie restriction is the outcome, even if there is 
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no effect on body weight. However, a predictive decrease in energy intake and body weight may 
be attributed to a food only after studies have successively established its satiety enhancing 
effects first on food intake and then on body weight in various populations (normal, overweight, 
and obese individuals), through a staging of the proof of a concept.166 
While oatmeal has in a past study,50 and in the present study been demonstrated to 
increase satiety at a single exposure, its effects on repeated exposures, food intake, and body 
weight remain to be established. Studies evaluating the effects of Olibra™, on satiety and food 
intake however, have been unable to replicate the effects on satiety or food intake demonstrated 
in early studies. In the present Olibra™ investigation, a pre-load test meal paradigm, a parallel 
design with double blind conditions that permitted within subject analyses, and products that 
were matched for taste, appearance, energy and macronutrient content, were used. The results of 
the study add to the mounting evidence provided through a multi-step proof of concept that 
Olibra™ is ineffective as a satiety enhancing or weight loss strategy.  
Differences in the macronutrient composition of foods produces differing effects on 
satiety, as each component has different interactions with the multitude of processes influencing 
satiety, described in the satiety cascade. From reviews that have been conducted,15, 27, 64, 65, 167 it 
appears to be well established that high-protein foods and diets can exert a potent effect on 
appetite regulation. In the study investigating the satiety effects of oatmeal and  a popular oat-
based RTEC, the protein content of the meals differed by an amount that was far less than the 
proportion that has been demonstrated to facilitate an increase in satiety. Nevertheless, the 
overwhelming evidence related to protein-induced satiety presented in the literature15 precludes 
the exclusion of protein as a mediating factor in the increase in satiety observed following 
consumption of the oatmeal breakfast as compared with the RTEC.  
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The Gi of oatmeal and the RTEC did not differ despite the higher fiber content of oatmeal 
as compared with the RTEC, which led to the inference that the difference in the satiety 
enhancing effects of the two products was not mediated by the Gi. The characteristics of a food 
and other dietary factors affecting food digestibility, GI motility, or insulin secretion  influence 
the Gi.92 Therefore, Gi values cannot be interpreted in isolation. However, inconsistencies in the 
data,17, 18 and considerations of practicality render the clinical relevance of the concept of Gi 
debatable. 
Consumption of viscous soluble fiber delays gastric emptying and intestinal transit. 
Prolonged exposure of the intestinal mucosa to nutrients stimulates the release of peptides which 
then function as satiety hormones or activate neural pathways.29 Oats contain significant amounts 
of ß-glucan, a viscous soluble fiber which displays a high viscosity at relatively low 
concentrations.119 Viscosity is an exponential function of the concentration of ß-glucan in 
solution and its molecular weight.131 The main factors affecting solubility are temperature, 
moisture content, and any other factors that interfere with penetration of water and diffusion of 
the dissolved material.129 Variations in the source, processing treatments, and interactions with 
other components in the primary source or the composite food matrix affect the amount, 
solubility, molecular weight, and structure of ß-glucan.130 Thus, the physiologic action in the 
gastrointestinal tract and thereby the functionality of ß-glucan differs from one product to 
another. Oatmeal had a higher content of ß-glucan (2.3g) than the RTEC (1.7g), but it is possible 
that ß-glucan delivered through oatmeal may also be more bioavailable. 
Relatively high levels of insoluble fiber (18-33g) in a meal have been shown to increase 
satiety.87, 105 The insoluble fiber content of the oatmeal and the RTEC was only a fraction of 
these amounts and may have been too small to influence satiety. Although the energy density of 
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a food is largely determined by the water content, fiber does play a lesser role. Foods with a 
higher energy density are more satiating than foods with a lower energy density.33 The total fiber 
content of oatmeal was higher than the RTEC which would have contributed to lowering its 
energy density and may have had a role to play in its greater effect on satiety as compared with 
the RTEC. Thus, it appears that the major role in enhancing satiety appears to have been played 
by the total fiber content especially the ß-glucan content of oatmeal. 
Fat is higher in energy density than carbohydrate or protein yet it can generate potent 
satiety signals. Thus, despite its paradoxical nature, the satiating effects of fat may be exploited 
as a means of regulating food intake, making it an attractive target for the development of 
functional foods. Fats have been shown to reduce hunger when present in the GI tract by eliciting 
satiety signals.22 Delaying lipolysis results in the exposure of more distal parts of the small 
intestine to fats and fatty acids. Exposure of the ileum to lipids activates the ileal brake, a distal 
to proximal feedback mechanism,35 that delays gastric emptying,36, 138 prolongs GI transit time 37 
and influences satiety.38, 39, 139  The inhibitory effects of the activation of the ileal brake are a 
result of the interaction of neural and humoral signals.31 
The extent to which the ileal brake has a role in satiety and food intake under physiologic 
conditions is influenced by the physicochemical properties of fat. The effects are more 
pronounced with LCT (≥12 carbons) than shorter chain fatty acids.22, 40, 41 whereas the role 
played by the degree of saturation in modulating the effects of fat on the GI tract has not been 
resolved fully.43, 44 However, digestion to fatty acids is an essential step.141 After ingestion of a 
regular meal only a small proportion of ingested nutrients reach the ileum. Thus, delaying 
lipolysis and reducing the absorption rate is crucial for stimulation of the ileal brake. It has been 
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shown that galactolipids reduce the rate and extent of lipolysis by sterically hindering the 
penetration of pancreatic colipase and lipase at the oil-water interface in the duodenum.145  
Olibra™ is a fat emulsion comprised of fractionated palm, and oat oil in the proportion of 
95:5. The palm oil is emulsified by hydrophilic galactolipids derived from oat oil.146  Early 
studies,23-25  all crossover designs, reported a reduction in energy intake and suppressive effects 
on appetite ratings in the short term, following consumption of the Olibra™ emulsion. Two 
subsequent studies failed to confirm the reduction in energy intake,45, 46 though a suppressive 
effect on appetite ratings was demonstrated.46 The beneficial effects of Olibra™ on body 
composition and weight maintenance, after weight loss, were demonstrated in one study,149 
however, in another study150 no effect on weight was observed, but body fat mass decreased, 
after an initial weight loss period.  
Studies that employed methods of delivering the emulsion directly into the GI tract 
demonstrated a delay in GI transit.146, 159 However, when ingested orally, this fat emulsion may 
not elicit the GI responses manifested by an intragastric or intraduodenal administration.  The 
lack of reproducibility of the beneficial effects of Olibra™ demonstrated in early studies 
suggests that in the dynamic environment of the GI tract, the emulsion may not resist digestion 
which is necessary for stimulating an increase in satiety and a reduction in food intake. A review 
of published studies investigating Olibra™ provided overwhelming evidence that further 
investigation of Olibra™ as a means of regulating appetite and satiety, and thereby food intake, 
is not warranted. 
The studies had some limitations. Although the effects on satiety have been associated 
with hormonal action, hormone levels were not measured in either study; hence, it is difficult to 
draw any definitive conclusions as to the effects of hormones on appetite and satiety. Subjects in 
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both studies were asked to maintain a 10-12 hour overnight fast, but no control was exercised 
over subjects’ food intake prior to each test day which may have influenced the results. The 
samples in both studies were relatively small, convenience samples, including predominantly 
female subjects, thus the generalizability of the results was compromised. The effects of oatmeal 
or the RTEC preload on subsequent food intake were not measured thus; the effects on 
regulation of food intake are unknown. Only short term satiety was measured, thus, the 
possibility of recurrent activation of the satiating mechanisms was not assessed. Further, the 
nutrient contents of the two breakfast cereals were not matched therefore; the effects of each 
nutrient on satiety could not be clearly differentiated. Lastly, in the study investigating the effects 
of Olibra™ on satiety, no information on subjects’ usual intake was obtained, to determine if 
previous patterns of nutrient exposure were related to the results.  
Postponing lipolysis and lipid absorption through manipulation of the physicochemical 
properties of fat, or increasing the viscosity of food products, so as to stimulate appetite and 
satiety mechanisms appears to be biologically plausible. Development of functional foods that 
target these physiologic responses may have a role in improving adherence to diet plans by 
prolonging the interval between meals, and perhaps reducing energy intake. However, it is 
possible that the satiety response at one exposure may be different at other exposures considering 
the learned and conditioning responses, and myriad factors affecting satiety.  
Thus, studies that demonstrate the satiety enhancing effect of foods or the lack of it, 
contribute to the literature exploring the field of functional food development. Additionally, 
claims to satiety are different from claims to reduction in food intake or body weight. Any 
irrational expectations implied in satiety claims may thus be verified.    
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